

Index

In this index, boxes are indicated by *box*; tables are indicated by *t*; figures are indicated by *fig*.

- Abas, M., 61
- acceptance and commitment therapy (ACT), 127–128, 132–133, 135*box*, 180, 422*t*29.1, 432
- Access to Allied Psychological Services (ATAPS), 376, 381*box*
- access to mental health care.
See also anxiety; *headings under depression*; IAPT programme; psychological therapies
- aims/definitions/features of, 401–402
- in the AMP project, 390
- for asylum seekers/refugees, 322
- candidacy eligibility for health care and, 390
- care pathway restructuring and, 394
- CMHT and, 393–394, 395, 396
- collaborative care and, 392, 396, 397
- co-location and, 396
- for common mental health problems, 386, 388*box*27.1
- communication improvement for, 394–395
- computer-based CBT and, 391, 397*box*, 397
- consultation-liaison model and, 396, 403–404
- continuity in, 4, 41–42, 45, 381
- demand for, 394
- depression (major) and, 393–394
- for ethnic minorities, 303, 304–305, 305*box*21.2, 307*box*, 386–387, 390
- financial incentives for, 259, 392–393, 397*box*
- improvement in, for IAPT, 386, 388
- improvements in (overview), 386–397
- integrated care and, 395–396
- inverse care law and, 176–177*box*12.1, 176, 397
- IT improvements to, 387*box*27.1
- key points of, 397*box*
- link-working and, 395
- medication availability and, 386
- models of, 394
- NICE guidelines on improvement of, 387–388*box*27.1
- patient-centredness and, 434
- as PCMH central feature, 381
- practitioner behaviour and, 387
- primary-specialist interface and, 393–395
- psychotic disorders and, 217–219, 393–394
- QOF financial intervention for, 259, 392–393, 397*box*
- from remote locations, 390–391, 395, 397
- shared care and, 395
- for SMI patients, 288, 391–392
- socioeconomic limitations to, 386
- in sociological contexts, 30–31, 36*box*
- stigmatization limiting, 386–387
- surveys regarding, 386
- via technology, 390–391, 395, 397
- telephone-based, 387*box*27.1, 391, 394–395
- traditional referrals and, 393–394
- unreceived, 396–397
- ADHD. *See* attention deficit hyperactivity disorder
- adjustment disorder, 88–89
- Adult Psychiatric Morbidity Survey, 16, 126, 201
- affective disorders, 80, 104, 281*t*20.3. *See also* bipolar disorder
- Africa, 54, 55, 57, 63, 74–75, 319. *See also* Black populations
- African-Caribbean ethnic minorities. *See also* Black Caribbean ethnic minorities
- dementia risk factors among, 163–164
- depression and, 8, 301, 303–304
- post-natal depression in, 29–30
- registration levels in PCMH, 28–29
- schizophrenia rates in, 300–301, 305
- agoraphobia characteristics of, 128–129*t*9.2
- exposure therapy for, 132–133, 135*box*
- and panic disorder and, 129–130
- in PCMH vs. community care, 127
- prevalence of, 125, 126*t*9.1
- psychological therapies for, 133
- triggers of, 128–129*t*9.2
- AIDS/HIV, 57, 58. *See also* HIV
- alcohol dependence overview, 260
- Alcohol Use Disorders Identification Test for, 254*box*18.2, 255
- AUDIT for, 254*box*18.2, 255, 256*box*18.3, 258
- benzodiazepine use and, 244–245
- in case study, 262
- community-based programmes for, 260

- definitions and characteristics, 252
 detoxification, 260–261
 drinking histories and, 255–256
 hallucinations in, 252*box*18.1
 health effects of, 253
 medication prescribed for, 260, 262*t*18.1
 mental illness classifications and, 70, 234
 NICE guidelines on, 261*box*18.5
 prevalence of, 18*t*2.1
 referrals to health services for, 260
 screening for, 254*box*18.2
 withdrawal from, 254*box*18.2, 260, 261*box*18.5
- alcohol use problems overview, 251, 263*box*18.6
 alcohol trends and, 252–253
 Alcohol Use Disorders Identification Test for, 254*box*18.2, 255, 258
 Alcoholics Anonymous and, 256*box*18.3, 262, 484
 anxiety caused by, 128
 AUDIT for, 254*box*18.2, 255, 256*box*18.3, 258
 barriers to brief intervention in, 263*box*
 barriers to PCMH intervention for, 259
 brief intervention for, 254, 256*box*18.3, 257*box*18.4, 258, 259, 263, 362*t*25.6, 446
 CAGE questionnaire on, 255
 cannabis in, 262
 cardiovascular disease and, 253
 in case study, 258
 comorbidity and, 247, 260, 261*box*18.5
 cost savings for, 364
 definitions and characteristics, 251–252
 delirium caused by, 156*box*11.2
 detoxification, 256*box*18.3
 diagnosis of, in PCMH, 253
 drinking histories and, 255–256
 drug overdose involving, 242
 Fast Alcohol Screening Test for, 255
 FRAME intervention for, 256*box*18.3
 GBD report on, 253
 as a global issue, 253, 263*box*
 among GPs, 481, 484
 harm caused by, 238, 253, 256*box*18.3
 IBA intervention for, 253–254, 260
 interventions in, 360
 key points of, 263*box*
 life expectancy reduced by, 360
 management of, 253, 256*box*18.3, 257–258, 259
 maternal, 156*box*11.2, 237
 mental illness classifications and, 70, 234
 mortality from, 253
 ODHIN trials in, 260
 osteoporosis and, 291*t*20.5
 parental, 238
 PCMH implementation of IBA, 260
 PCMH screening opportunities for, 254*box*18.2
 during pregnancy, 358
 prevalence of, 354*t*25.1
 prevention of, 359
 prognosis for, 262–263
 psychological therapies for, 422*box*29.1
 recording of, 259
 RTCs for, 258
 screening for, 266*box*18.2, 253–254, 255–256, 258–259
 SDGs for, 59
 vs. sensible alcohol use, 251
 as suicide risk factor, 112*box*8.3, 233–234
 support groups for, 262
 talking therapies for, 257
 in young people, 355*t*25.3
 Alderson, S.L., 42
 Allberry, Henry, vii, 480–486
 Alliance Against Depression programme, 6
 Alma Ata conference and declaration, 2, 6, 57, 58*box*5.2
 Alzheimer's disease. *See* older people (dementia in)
 Alzheimer's Society, 16, 167, 168, 170
 AMP (Improving Access to Mental Health in Primary Care) programme, 390
 Angermeyer, M.C., 41
 anorexia nervosa, 78–79*box*6.2, 267–268*t*19.1, 269, 273, 355*t*25.4. *See also* eating disorders
 antidepressant medications for anxiety, 92, 95–96, 193
 for bulimia nervosa, 193
 for children and adolescents, 206*t*14.2
 depression and, 93, 94–96, 97, 98*box*, 159, 160–161, 386
 discontinuation symptoms and, 95–96
 dyslipidaemia and, 280–281
 for dysthymia, 88
 effectiveness of, 20
 ethnic minorities' rejection of, 303
 lithium and, 293
 long-term use of, 98
 for older people, 156*box*11.2, 159, 160–161, 162
 overprescribed, 33
 patients' concerns about, 47, 49–50*box*
 for perinatal mental health problems, 186, 193
 for prisoners/offenders, 344
 for PTSD, 193
 rates of, increasing, 16
 recurrent depression response to, 477
 RTCs of, 88
 for schizophrenia, 277
 for sexual problems, 334
 in stepped care trials, 408
 treatment decisions regarding, 473–474, 476
 withdrawal from, 230
 antipsychotic medications in case studies, 213, 226
 diabetes and, 286
 dyslipidaemia and, 280–281
 in emergencies, 229
 hyperprolactinaemia and, 290
 lithium and, 293

- antipsychotic (cont.)
 low-dose, 220–221
 osteoporosis and, 291
 sexual problems and, 290
 side effects of, 218
 vs. untreated psychosis, 215
 weight gain from, 289
- anxiety. *See also* collaborative care; generalised anxiety disorder; panic disorder; prison populations and offenders; sexual problems; social anxiety disorder (social phobia); stepped care
 overview, 125–135
 access to PCMH for, 386
 in adjustment disorder, 88–89
 antidepressant medication for, 193
 in asylum seekers/refugees, 311, 312, 316, 318
 benzodiazepine use and, 244
 burdens of, 373, 401
 comorbidity in, 74–75
 definitions and characteristics, 125
 depression combined with, 75*fig*6.1, 87, 126, 127, 135, 159, 161
 drug misuse and, 240, 246–247
 epidemiology and classification of, 125–126
 in families of drug users, 247–248
 among GPs, 480, 481
 health anxiety/illness disorder, 131
 helplessness vs. hopelessness in, 127
 Hospital Anxiety and Depression Scale, 80
 IAPT treatment for, 46
 inventories and scales measuring, 129
 key points of, 135*box*
 LTCs and, 175, 180
 management of, 180, 376–377
 mindfulness-based interventions for, 132–133
 normal vs. abnormal, 125
 PCMH treatment of, 3, 8, 12
 prevalence of, 16, 125, 401
- PROMs monitoring, 129
 rates of, increasing, 25
 Revised Child Anxiety and Depression Scale, 203–204
 screening and case-finding of, 127
 secondary care referrals for, 134
 severity measurements of, 92
 traditional healing and, 63
- anxiety disorders. *See also* generalised anxiety disorder
 in acute mental health emergencies, 228
 antenatal, 186–187
 benzodiazepines for, 133–134
 burdens of, 125–126
 in case studies, 140–141
 CBT for, 46–47
 in children and adolescents, 191, 200–201, 203
 cost savings for, 364
 definitions and characteristics, 128*t*9.2–129*t*9.2
 depression combined with, 135*box*
 detection of, 19
 diagnosis of, 127–131, 135*box*
 eating disorders and, 268
 first, second and third line medication for, 133*t*9.3
 functional impairment resulting from, 132–134
 GAD-7 score for, 80
 IAPT treatment for, 46
 interventions for, 132–134
 key points of, 135*box*
 in LAMI countries, 63
 management of, 131–134, 376–377
 medication prescribed for, 133–134, 135*box*
 NICE guidelines on, 131–134
 perinatal, 186–187, 191
 physical symptoms in, 125, 127–131, 128–129*t*9.2, 135*box*
 presentations in PCMH, 127–129
 prevalence of, 126*t*9.1
 psychological therapies for, 135*box*, 422*box*29.1
 recognition of, 132
- screening and case-finding of, 135*box*
 secondary care referrals for, 135*box*
 starting ages of, 354*t*25.2
 substance misuse and, 75–76
 treatment-refractory anxiety disorders, 134
 triggers of, 128–129*t*9.2
- Arroll, Bruce, vii, 125–135
 Asia, 55, 57, 63, 74–75, 301. *See also* ethnic minorities; South Asian minorities; South East Asia
 Asian ethnic minorities, 301, 303–304, 386. *See also* South Asian minorities
 asylum seekers and refugees. *See also* ethnic minorities
 overview, 311–322
 access to mental health care for, 322, 390
 anxiety in, 311, 312–313, 316, 318
 assessment of psychological problems in, 312–313
 building trust with, 314
 in case studies, 312, 316, 319
 children as, 318, 320
 CMHT services for, 321
 cultural issues of, 312–314
 defined, 311
 depression in, 311, 319
 detection of psychological problems in, 312–313
 detention of, 305, 311, 315*box*22.1, 316, 317, 319
 diagnosis of psychological problems in, 313, 322*box*
 epidemiology and classification of, 311
 in exile, 311, 312, 314, 317–318, 322*box*
 guidelines for practitioners serving, 322
 interpreters for, 314–315, 318
 issues common to, 315–318
 management issues for, 318–320
 medication prescription for, 320, 322*box*
 older people as, 318
 political issues among, 313, 314, 318–319
 poverty among, 311, 313, 322*box*

- principles of working with, 313–315
- psychological problems experienced by, 312–313
- PTSD among, 311, 313
- rape victims among, 312, 313, 315*box*22.1, 316*box*22.2, 319
- refugee community organizations for, 321
- reports written by GPs on, 321
- screening for psychological problems in, 312–313
- stigmatization of mental illness in cultures of, 314
- stress among/distress among, 311, 312–313, 316, 317, 318–320, 322*box*
- substance misuse among, 317
- suicide among, 317
- support services for, 321
- therapies and counselling for, 319–320
- torture victims among, 311, 312, 313, 315*box*22.1, 315–316, 316*box*22.2, 318, 320
- traumatic events experienced by, 315*box*22.1, 318
- women as, 313, 316, 317–318, 319
- ATAPS (Access to Allied Psychological Services), 376, 381*box*
- attention deficit hyperactivity disorder (ADHD)
- continuing into adulthood, 203
- diagnosis of, 202
- medication for, 206*t*14.2
- as neurodevelopmental disorder, 203
- parenting interventions for, 207
- pregnancy issues and, 358
- prevalence of, 354*t*25.1
- in prisoners/offenders, 343
- AUDIT (Alcohol Use Disorders Identification Test). *See* alcohol dependence; alcohol use problems
- Australia
- Access to Allied Psychological Services in, 376, 381*box*
- antidepressant treatment for depression in, 97
- antipsychotic medication tests in, 220
- asylum seekers in, 311, 317
- Beyond Blue project in, 6
- collaborative care in, 406
- early psychosis intervention in, 216–217
- GP's preferred over specialists in, 374
- health anxiety/illness disorder, 131
- Lester Positive Cardiometabolic Health tool in, 294
- nurse training in, 377–378
- PCMH funding issues in, 7
- telemedicine in, 395
- Austria, 374, 375
- autism spectrum disorder, 200, 203, 354*t*25.1
- Balint, Michael, 30, 73, 453
- Balint groups, 453, 485
- Barnett, K., 175
- Bauer, M.S., 406
- Beck Depression Inventory (BDI), 80, 92, 93*t*7.1, 129
- BED. *See* binge eating
- Bee, P.E., 391
- behavioural activation (BT)
- in case studies, 179*box*12.2, 424–425, 431
- as CBT, 424*box*29.2, 434*box*
- in collaborative care, 404
- for depression, 410, 429–430, 430*fig*29.6, 431, 446
- effectiveness of, 178, 403, 431
- effects of, 161
- patients' preferences for, 30
- Belgium, 70–72, 373–374, 375
- benzodiazepines
- alcohol dependence and, 244–245, 260
- for anxiety disorders, 135*box*
- controversial legacy of, 32–33
- counterindications for, 95, 133–134
- in emergencies, 228
- heroin use combined with, 242
- misuse of, 244–245
- for postnatal depression, 193
- for prisoners/offenders, 348
- risks of, 348
- as second- and third-line medication for anxiety, 133*t*9.3
- withdrawal from, 230
- bereavement
- cultural bereavement, 311
- depression and, 87, 90*box*7.2
- and suicide among young people, 114
- suicide and, 112*box*8.3, 118, 121
- Berg, Insoo Kim, 119
- Beyond Blue (depression treatment project), 6
- Bhugra, D., 305
- bibliotherapy, 46, 93–94, 132, 425, 433–434
- Bill and Melinda Gates Foundation, 57
- binge eating, 187, 267–268*t*19.1, 267–269, 271–272*t*19.2. *See also* eating disorders
- bipolar disorder
- antidepressants not recommended for, 95
- cardiovascular disease and, 281*t*20.3
- collaborative care for patients with, 405–406
- diagnosis of, 92
- life expectancy and, 279*t*20.2
- lithium prescribed for, 294
- medical treatments for, 193, 279–280
- mortality and, 278
- patients' descriptions of, 41
- PC vs. specialist interests in, 447
- and perinatal mental health problems, 194
- postpartum, 185
- prevalence of, 354*t*25.1
- as a psychosis classification, 214*box*15.1
- QOF for, 294, 393
- secondary care treatment of, 12
- smoking and, 218, 281*t*20.3
- Black Caribbean ethnic minorities, 29–30, 301, 303, 305

- Black populations. *See also*
 African-Caribbean ethnic minorities
 acceptance of PCMH by, 303
 access to mental health care for, 390
 coercion in, 28–29
 depression diagnoses in, 303
 health services underused by, 386
 overrepresented in PCMH, 28–29
 psychosis in, 215
 Strong-Black-Woman self-image, 29–30
- Bleuler, Manfred, 219
- BN (bulimia nervosa). *See* eating disorders: bulimia nervosa
- Bodily Distress Syndrome (BDS), 138, 140*fig*10.1, 141–142
- Bordieu, P., 24–25
- Borglin, G., 388
- Botswana, 61
- Bower, P., 394
- Brazil, 18*t*2.1, 61, 80
- brief intervention
 for alcohol use problems, 254, 256*box*18.3, 257*box*18.4, 258, 259, 263, 362*t*25.6, 422*t*29.1, 446
 barriers to, 259, 263*box*
 cost effectiveness of, 258, 362*t*25.6, 364
 effectiveness of, 94, 258, 263*box*
 elements of, 257*box*18.4
 implementation of, 260, 263*box*
 nurses training in, 258–259
 practitioner's skills in, 434
 problem-solving therapy and, 427–428, 434
- British Network for Alternatives to Psychiatry campaign, 39–40
- Bulgaria, 375
- bulimia nervosa. 78–79*box*6.2, 193, 267–268*t*19.1, 267, 269, 273. *See also* eating disorders: bulimia nervosa
- bullying, 201, 205, 231*box*16.2, 318, 359, 364, 482–483*t*33.1
- Burnett, Angela, vii, 311–322
- Burns, Tom, 396, 454–455
- Burr, J., 41
- Buszewicz, M., 379
- Byng, Richard, vii, 343–350
- Cambodia, 311
- CAMHS (child and adolescent mental health services), 204, 205*t*14.1, 207, 209
- Campaign Against Psychiatric Oppression, 39–40
- Campbell, S.M., 42–43
- Campion, Jonathan, vii, 353–365
- Canada
 anxiety disorder rates in, 126
 attitudes in, toward mental health problems, 378, 380
 audiotape teaching in, 451*box*30.3
 early psychosis intervention in, 216–217
 health expenditure in, 60*t*5.2
 migrants' ethnicities in, 300
 problem-based interviewing in, 451
 refugees in, 320
- cardiovascular disease. *See* alcohol use problems; obesity; physical health of people with mental illness; psychotic disorders; public mental health; schizophrenia; smoking
- Care Quality Commission (CQC), 3, 49
- CBT. *See* cognitive behavioural therapy
- CCGs (Clinical Commissioning Groups), 49, 349
- Cerel, J., 118
- Chapman, T., 41
- Chew-Graham, Carolyn A., vii, 1–9, 153, 172*box*11.8, 300–307, 459–469
- child and adolescent mental health problems
 overview, 200–209
 abuse as stressor for, 201
 ADHD among, 200, 202, 203, 206*t*14.2, 207
 alcohol use problems, 355*t*25.3
 alcohol use problems among, 354*t*25.1
 anxiety disorders among, 200–201, 204, 205*t*14.1, 207, 208
 autism spectrum disorders among, 200, 203, 354*t*25.1
 behaviour disorders among, 200–202, 206*t*14.2, 208–209
 bereavement among, 114
 bullying as stressor for, 201
 burdens of, 203
 CAMHS specialist care for, 204, 205–207, 209
 in case studies, 207–208
 child abuse and, 357
 classifications of, 78–79*box*6.2, 201
 common mental problem prevalence among, 200
 comorbidity in, 203
 conduct disorders among, 201–202, 206*t*14.2, 208–209, 354*t*25.1, 355*t*25.3
 continuing into adulthood, 203, 209–210*box*, 357
 depression among, 200–201, 204, 205*t*14.1, 207–208
 detection of, 200
 diagnosing and recognizing, 203–204, 209–210*box*
 drug use disorders among, 354*t*25.1
 early intervention in, 209, 357, 359
 emotional disorders among, 354*t*25.1, 355*t*25.3
 exclusion from school because of, 355*t*25.3
 health risk and exclusion levels and, 355*t*25.3
 hyperkinetic disorder among, 354*t*25.1
 impulse control and, 201–202
 intervention levels in, 204, 205*t*14.1
 key points of, 209–210*box*
 management of, 204–207
 medication prescribed for, 205–207, 206*t*14.2
 MUS and, 202
 neurodevelopmental disorders and, 203

- oppositional defiant disorder, 201–202, 203, 206*t*14.2
 panic disorder among, 129–130
 PCMH and, 354*t*25.1
 phobias among, 130
 physical health problems and, 200, 203
 physical illness and, 202
 policy and future directions for, 209
 presentations of, 200–203
 prevalence of, 200, 354*t*25.1
 psychological interventions in, 207
 psychotic disorders among, 220
 questionnaire measurements of, 203–204
 referrals to health services for, 202, 204, 205*t*14.1
 self-harm among, 114, 201, 355*t*25.3
 self-help therapies for, 204–205
 severe impairment disorders, 200
 smoking and, 354*t*25.1, 355*t*25.3
 stepped care for, 209–210*box*
 suicide and, 114, 201
 child mortality, 57, 58*box*5.2, 58
 Chile, 18*t*2.1, 20, 404
 China, 18*t*2.1, 59
 Chronic Care Model, 178
 chronic fatigue syndrome, 19, 138, 140–141
 Cipriani, A., 464–465
 City and Hackney Clinical Commissioning Group, 45
 Clinical Commissioning Groups (CCGs), 49, 195, 349
 CMHT (Community Mental Health Team), 217, 247, 393–394, 395, 396
 Cochrane reviews (*Cochrane Database of Systematic Reviews*), 105–106, 191, 194, 207, 338
 cognitive analytic therapy (CAT), 348, 432, 478
 cognitive behavioural therapy (CBT). *See also*
 mindfulness-based therapy; talking therapies
 for anxiety disorders, 46–47
 behavioural activation in, 424*box*29.2, 425
 brief psychological interventions in, 424*box*29.2
 for childhood depression, 208
 cognitive analytic therapy, 432
 cognitive model of, 429*fig*29.5, 429*box*29.5
 computer-based CBT, 34*box*3.1, 35, 46, 94, 97, 391, 397*box*, 424*box*29.2
 defined, 428
 for depression, 20, 94, 96–97, 98*box*, 161
 depression descriptions outside models of, 40
 for fatigue issues, 446
 as first line of treatment, 135*box*
 for GAD, 132–133
 health technologies for, 425
 high intensity CBT, 406–407
 in the IAPT programme, 376, 389
 intervention economics of, 362*t*25.6
 limitations of, 26–27, 34*box*3.1
 mindfulness-based therapy in, 432–433
 for MUS, 146
 as new field in PCMH, 32, 36*box*
 for panic disorder, 132–133
 patients' preferences for, 30
 for perinatal mental health problems, 191
 for postnatal depression, 192*box*13.2
 psychological therapies and, 420
 in psychological therapy referral model, 403
 for psychotic disorders, 220–221
 from remote locations, 391
 self-help therapies and, 93, 424, 428–429
 for sexual problems, 335–336
 shortage in practitioners of, 46
 stepped care and, 421*fig*29.1
 via technology, 391
 third wave of, 96–97, 132–133
 in treatment decisions, 473–474, 475
 as treatment model, 71*t*6.1
 Cole, Frances, 420–434
 Cole-King, Alys, vii–viii, 103–119
 collaborative care
 overview, 401–413
 access to PCMH care improved by, 390, 391–392
 aims and principles of, 404, 413*box*
 in AMP project, 390
 anxiety outcomes in, 404
 cardiovascular disease and, 179
 case managers in, 377, 404, 405, 406, 412–413, 413*box*
 Chronic Care Model as basis for, 178
 chronic disease management and, 404
 for common mental health/problems, 178–179
 consultation-liaison model as precursor to, 403–404
 for depression, 6, 97, 404–405
 effectiveness of, 404–405, 413*box*
 future developments for, 413
 IT resources in, 405
 key points of, 413*box*
 for LTCs, 179*box*12.2
 multi-professional communication enhanced in, 405
 for MUS, 146
 nurses' involvement in, 379
 PCMH education and, 379
 PCMH teams and, 373
 in the primary care/specialist interface, 393, 396
 psychological therapy components of, 405
 service delivery issues in, 405, 413*box*
 for SMI patients, 397, 405–406

- collaborative care (cont.)
 for South Asian women, 390
 in suicide prevention, 115, 119–120*box*
 telephone-based, 404, 412–413
 treatment models, 30
 trials of, 404
- Collinson, Sue, vii–viii, 39–49
- Colombia, 61
- common mental health
 problems. *See also* anxiety; *headings under depression*
 overview, 401–413
 access to care for, 386
 collaborative care models for, 397
 IAPT programme and, 376, 388–389
 identification of, 376–377
 intervention gaps in, 361–364
 in LAMI countries, 61–62
 LTCs and, 175, 177–180
 management of, 376–377, 401–402
 models of service for, 375, 402–403
 monitoring of, 92, 129, 177–180
 NICE guidelines on, 387–388*box*27.1
 PCMH teams' roles in care of, 376–378, 381*box*
 perinatal, 195, 196*box*
 poverty and, 63–64
 prevalence of, 16, 17, 18*t*.1, 200, 379, 403
 psychological therapies for, 406–407
 remotely provided therapy for, 391
 screening for, 127
 social views of, evolving, 24
 socioeconomic status and, 357, 373–374
 sociological factors in, 462
 talking therapies for, 25
 treatment decisions regarding, 476–477
 treatment not received for, 396–397
- Community Mental Health Team (CMHT) model, 217, 247, 393–394, 395, 396
- comorbidity. *See also* morbidity; multimorbidity
 alcohol use problems and, 247, 260, 261*box*18.5
 in anxiety, 126
 in child and adolescent mental health problems, 203
 depression and, 92, 159
 in depression assessment and management, 449–450*box*30.2
 diagnostic systems and, 82*box*
 drug use disorders and, 247
 in eating disorders, 267, 269–270
 LTCs and, 175, 177
 management of, 177–178
 mental health problems presenting with, 4, 73, 74–76
 MUS and, 143
 National Comorbidity Survey, 14
 nurse monitoring of, 380
 in older people, 162*box*11.5
 PCMH teams addressing, 373–374
 PICO treatment and, 476*box*32.1
 in prisoners/offenders, 343
 RCTs and, 475
 research including patients with, 478
 schizophrenia and, 278*box*20.1
 in sexual problems, 331, 336
 in South Asian ethnic minorities, 301
 surveys on, 14
- computer-based cognitive-based therapy (cCBT), 34*box*3.1, 35, 46, 94, 97, 391, 397*box*, 397
- conduct disorders, 201–202, 206*t*14.2, 208–209, 354*t*25.1, 355*t*25.3, 362*t*25.6, 364
- consultation-liaison model, 375, 396, 403–404
- coronary heart disease, 41, 97, 176–177*box*12.1, 179, 392–393
- Coughtrey, Anna, vii–viii, 200–209
- Coupe, N., 467
- Coventry, Peter, vii–viii, 175, 181*box*12.3, 401–413
- CQCs (Care Quality Commissions), 49
- Creswell, J., 466–467
- Czech Republic, 375
- DALYs (disability adjusted life years), 16, 17, 89–90. *See also* burdens of specific mental disorders
- Day, Ed, vii–viii, 236–248
- de Shazer, Steve, 119
- Defeat Depression Campaign, 6
- delirium. *See also* older people (delirium in)
- Delphi study method, 55, 254
- delusions. *See also* hallucinations
 in acute psychosis, 228
 in case studies, 170–171, 226
 in older people, 153, 154, 160, 170–171
 in postpartum psychosis, 187
 in psychosis detection, 216
 in suicidal thought examination, 112*box*8.3
- dementia. *See also* older people (dementia in)
 burdens of, 17
 disabling nature of, 17
 interventions for, 359
 in LAMI countries, 20, 163–164
 PCMH treatment of, 14
 secondary care treatment of, 12
 specialist care for, 19
- Denmark, 70–72, 374, 375
- describing of
 medications, 47
- depression. *See also* antidepressant medications; child and adolescent mental health problems; older people (depression in); perinatal mental health problems (postnatal depression); PHQs (Patient Health Questionnaires); prison

- populations and offenders;
sexual problems
- depression (general)
overview, 87–98
access to PCMH treatment
of, 97, 98*box*
adjustment disorder and,
88–89
alcohol use problems and, 240
Alliance Against
Depression, 6
Alliance Against Depression
programme, 6
anxiety combined with,
75*fig*6.1, 87, 126, 127, 135,
159, 161
Beck Depression Inventory
for, 80, 92, 93*t*7.1, 129
behavioural activation
for, 431
and bereavement, 87
Beyond Blue project, 6
bipolar disorder and, 92
burdens of, 373, 401
CBT treatment for, 20
chronic and recurrent, 40,
42–43, 74, 96*box*7.3,
162*box*11.5, 379, 381*box*,
433, 474, 477
collaborative care treatment
models, 6
comorbidity and, 74–75, 92
continuum of severity of, 15
coronary heart disease and,
97, 379
cost savings for, 364
criteria of, 70, 72*t*6.2
cultural expressions of,
29–30, 188
DALYs lost to, 89–90
Defeat Depression
Campaign, 6
definitions and
characteristics, 87–89
detection of, 91–97
diabetes and, 286, 379
diagnosis of, 15, 17–18, 42,
72*t*6.2, 73, 89, 244, 304,
464–465
drug misuse and, 246–247
epidemic of, 98
epidemiology of, 74, 89–90
in ethnic minorities, 301,
303–304
external sources of, 40–41
fatigue and, 19
focus on, renewed, 6
functional impairment
and, 81
among GPs, 480, 481, 482, 484
Hampshire Depression
Study, 462
Hospital Anxiety and
Depression Scale, 80
IAPT treatment for, 46
intervention economics of,
362*t*25.6
interventions for, 359,
362*t*25.6
Inventory to Diagnose
Depression, 80
key points of, 98*box*
life expectancy and, 279*t*20.2
LTCs and, 91, 92, 175–176,
177–179, 180, 181*box*, 379
management of, 91–97,
376–377
medical education and, 446
medication comparison
studies for, 468
mindfulness-based
interventions for, 96–97
morbidity and, 74
multimorbidity and,
175–176
new approaches to treatment
of, 26
NICE guidelines on, 91
observational studies of, 462
Overcoming Depression
treatment programme,
93–94
patients' descriptions of,
40–41
PC vs. specialist interests
in, 447
PCMH assessment and
management of,
449–450*box*30.2
in PCMH attenders, 19,
45–46
PCMH research priorities
for, 97–98
PCMH treatment of, 8, 26,
39, 42–43
perinatal depression, 359
physical illness and, 90,
355–356
physical symptoms of, 41
poverty and, 286
prevalence of, 16,
354*t*25.1, 401
in primary- vs. secondary-
care patients, 474, 475
PROMs monitoring, 92
psychological therapies for,
98*box*, 422*box*29.1
questionnaires on, 93*t*7.1,
98*box*
rates of, increasing, 16, 17, 25
recall bias and, 462
recognition of, 90, 91–93,
98*box*, 181*box*
referrals of patients with, 474
research into diagnosis
of, 462
Revised Child Anxiety and
Depression Scale, 203–204
risk factors for, 90*box*7.2, 90
secondary care for, 96*box*7.3
self-help therapies and,
406–407
severity measurements and,
90, 92
social stressors causing, 90
vs. somatic symptoms, 90
stepped-care
recommendations for,
8, 91
stigma removed from, 26
stress causing, 40
suicide and, 104, 118
suicide prevention and, 359
terminologies describing, 9
timing of treatment of, 89
traditional healing and, 63
trigger symptoms for, 87–88
women's help-seeking
responses in, 73
years lived with, 401
YLDs caused by, 89–90
- depression (major)
access to mental health care
lacking for, 393–394
antidepressant treatment
for, 95
bereavement and, 87, 159
in case studies, 473–475,
476–477, 478
detection of, 91
drug treatment aversion
and, 478
in families of drug users,
247–248
guideline recommendations
for, 473–474
life expectancy reduced by,
355*t*25.4

- depression (major) (cont.)
 management of, 91
 in older people, 162
 vs. other depression intensity levels, 89
 PHQ-9 assessment for, 88*box*7.1
 PICO treatment approach to, 473–475, 478
 prevalence of, 17
 questionnaires on, 93*t*7.1
 risk factors for, 81
 symptoms of, 88*box*7.1
 systematic reviews of, 464–465
 treatment decisions regarding, 473–475, 478
- depression (mild to moderate)
 access to PCMH for, 386
 antidepressants not recommended for, 93*t*7.1, 94, 95, 386
 bibliotherapy for, 93–94
 brief psychological therapies for, 94
 diagnosis/recognition of, 88
 digital mental health interventions for, 94
 disabling nature of, 17
 drug misuse and, 240
 internet-based CBT for, 93–94
 persistent, 93–94
 PICO treatment approach to, 476–477
 questionnaires on, 93*t*7.1
 recognition of, 90
 self-help therapies for, 93–94, 98*box*
 social difficulties of, 476–477
- depression (minor), 88, 89, 93*t*7.1
- depression (moderate to severe), 94–96, 97
- depression (postnatal/postpartum). *See* perinatal mental health problems (postnatal depression)
- depression (sub-syndromal), 87, 158–159
- depression (sub-threshold)
 adjustment disorder and, 88
 antidepressants not recommended for, 93, 94
 bibliotherapy for, 93–94
 brief psychological therapies for, 94
 detection of, 91
 diagnosis of, 88
 digital mental health interventions for, 94
 internet-based CBT for, 93–94
 management of, 91
 vs. other depression intensity levels, 89
 persistent, 93–94
 treatments for, 93
- Depression Attitude Questionnaire (DAQ), 378, 447
- Depression Awareness, Recognition and Treatment Programme (DART), 6
- DeRubeis, R.J., 409
- Di Bona, L., 411
- diabetes. *See also* physical health of people with mental illness
 cardiovascular disease and, 281*t*20.3
 in case studies, 113, 258, 302
 depression and, 286, 355–356, 379
 management of, 288
 medication prescribed for, 287
 mental illness and, 285*fig*20.2, 286*box*20.2, 289
 prevention of, 287–288
 QOF applied to hospital admissions for, 392–393
 screening for, 286
 SMI combined with, 380
 type 2, 113, 258, 285*fig*20.2, 286
- diagnosis and classification of mental illness
 overview, 70–82
 biomedical model of, 73–74
 cross-cultural application of systems of, 76
 distress vs. disorder in, 73
 in the DSM-5, 70–72
 in the ICD-10, 70–72
 impairment and disability measurements and, 81, 81*n*1
 interview schedules and, 80
 key points of, 82*box*
- morbidity problems in, 74–76
 as PCMH specific, 73, 76–77
 personality disorders and, 72
 physical, mental and social problems present in, 73–74
 recommendations for, 82
 screening tools and, 80
 severity measurements and, 80
 specialist-primary care communication in, 82
 specialists' recognition of, 73
 subthreshold disorders in, 76
 symptomology fluctuations in, 74
 systems of, in PCMH, 76–77, 82
 treatment models and, 71*t*6.1
 validity of, 74–76
 varieties of, increasing, 70–72
- Diclemente, C.C., 425–426
- Disability Assessment Schedule (WHO-DAS), 81
- disability-adjusted life years. *See* DALYs
- disruptive behaviour disorders, 200–202, 207, 209–210*box*
- distress. *See* stress and distress
- Dixon-Woods, M., 390
- Doncaster/Newham stepped care demonstration sites, 407–408, 411–413
- Dowrick, Christopher, vii–viii, 70–82, 138–148, 467
- drug dependence
 cannabis use and, 244
 definitions and characteristics, 238, 240–241
 in drug misuse spectrum, 236
 early age substance misuse and, 236–237
 harm caused by, 238
 heroin in, 242, 246, 343, 344*box*24.1
 interventions for, 241, 242–243, 244, 248*box*
 mental health services' involvement in, 70
 methadone treatment for, 242, 246, 348, 461
 MUS management vs., 146
 opiate substitution treatment for, 242, 248*box*

- opioids in, 242, 245
 pain management and, 245–246, 248*box*
 prescription drugs and, 32–33
 withdrawal from, 254*box*18.2
- drug use disorders. *See also* substance misuse/abuse overview, 236–248
 acutely disturbed behaviour caused by, 227*box*16.1
 anxiety caused by, 128
 assessment of, 236, 241, 248*box*
 benzodiazepines in, 244–245
 cannabis in, 215, 216, 236, 237*t*17.1, 239*t*17.2, 240, 243–244, 248*box*, 262
 cardiovascular disease and, 243
 in case study, 241
 CMHT services for, 247
 cocaine in, 236, 237*t*17.1, 238
 comorbidity and, 247
 definitions and characteristics, 237
 depression caused by, 240
 detoxification and, 244–245, 246
 diagnosis of, 238
 drugs promoting abstinence and, 260–261
 in DSM-5, 238
 ecstasy in, 227*box*16.1, 236, 237*t*17.1, 243
 emotional disorders and, 355*t*25.3
 family members affected by, 247–248
 among GPs, 481
 GPs' roles in treating, 236, 241, 248*box*
 hallucinogens in, 239*t*17.2, 243, 244
 heroine in, 238, 241, 242, 246, 344*box*24.1
 incarceration for, 344*box*24.1
 interventions for, 241, 242–243, 244, 248*box*, 360
 intravenous injections in, 238–241, 239*t*17.2, 242, 243
 key points of, 248*box*
 life expectancy reduced by, 355*t*25.4, 360
 maternal, 237
 mental health issues and, 246–247
 mortality from, 240, 245
 novel psychoactive substances in, 244
 opioids in, 237, 239*t*17.2, 242, 244, 245–246, 248*box*, 355*t*25.4
 overdosing in, 242
 parental, 238, 262
 physical consequences of, 238–240, 239*t*17.2, 248*box*
 poverty and, 240
 during pregnancy, 358
 presentation and treatment options, 240–241
 prevalence of, 354*t*25.1
 psychological consequences of, 240, 248*box*
 psychological therapies for, 422*box*29.1
 rates of, 236–237
 risk factors for, 237–238, 248*box*
 sedatives in, 239*t*17.2
 social consequences of, 240, 246–247, 248*box*
 as a spectrum, 236, 238
 stimulants in, 239*t*17.2, 240, 243, 244, 248*box*
 suicide and, 112*box*8.3, 233–234
 users' profiles, 236, 237*t*17.1, 240–241
- Druss, B.G., 406
- DSM-5 (*Diagnostic and Statistical Manual of Mental Disorders*)
 cross-applications of, 76
 depression-related updates to, 87
 diagnostic criteria for major depression in, 72*t*6.2
 as mental health classification system, 76–77
 MUS and, 138–139
 new diagnostic classifications in, 75
 PCMH adaptations lacking in, 79
 in perinatal settings, 186
 sexual problems in, 328, 336
 similarities with ICD-10, 15
 somatic disorders in, 131
 substance use disorder in, 238
 subthreshold disorders and, 76
 as US diagnostic/classification system, 70–72
- DSM-IV-PC (*Diagnostic and Statistical Manual of Mental Disorders*), 79, 336
- Dunham, W., 215
- dysthymia, 88, 477
- eating disorders. *See also* anorexia nervosa; binge eating; bulimia nervosa overview, 267–273
 barriers to intervention for, 269–270, 273–274*box*
 in case studies, 271–272*t*19.2
 comorbidity and, 268, 269–270, 273–274*box*
 definitions and characteristics, 267–268*t*19.1
 distress caused by, 267*t*19.1–268*t*19.1
 early intervention for, 269, 273–274*box*, 273
 EDNOS (eating disorders not otherwise specified), 267–268*t*19.1, 267
 empathy toward, 270
 epidemiology of, 268–269
 identification of, 270, 273–274*box*, 273
 initial management of, 273
 key points of, 273–274*box*
 life expectancy reduced by, 355*t*25.4
 medical consequences of, 272–273
 morbidity issues in, 267
 mortality from, 267, 268, 273–274*box*
 in multi-ethnic populations, 268, 273–274*box*
 obesity and, 268, 271–272*t*19.2
 PCMH consultations rates for, 269–270
 PCMH incidence rates, 268
 physical examinations for, 273
 pica eating disorder, 267–268*t*19.1

- eating disorders (cont.)
 prevalence of, 354*t*25.1
 questionnaires on, 270–271
 referrals to health services
 for, 271–272*t*19.2, 273
 risk assessment of, 273
 rumination disorders,
 267–268*t*19.1
 SCOFF questionnaire on,
 270–271
 screening for, 270–271
 stages of, 268–269,
 273
 stimulants and, 239*t*17.2
 in women, 268–269,
 273–274*box*u
 in young people, 268–269,
 270, 273–274*box*u
- ecstasy (MDMA). *See* drug use
 disorders; psychotic
 disorders
- ED. *See* eating disorders
- education and training
 model, 402
- education in mental health. *See*
 teaching and learning
 about mental health
- Egypt, 61
- Ekers, David, vii–viii, 420–434
- emergencies in primary care
 overview, 226–234
 acute confusional states as,
 227–228
 acutely disturbed behaviour
 as, 226–230
 antidepressant withdrawal
 and, 230
 benzodiazepine withdrawal
 and, 230
 in case study, 226
 comportment of health
 professionals in, 229
 compulsory hospitalization
 and, 234
 consultation approaches to,
 227, 228–229
 drug and substance misuse
 causing, 227*box*16.1, 227,
 234*box*
 dystonias as, 229
 iatrogenic states in, 229–230
 key points of, 234*box*
 lithium toxicity and, 230
 management of mental
 health problems, 229
 medication and, 228, 229
- mental health problems as,
 227*box*16.1, 227, 228–229,
 234*box*
- neuroleptic malignant
 syndrome as, 229–230
- non-psychotic mental health
 problems and, 228
- physical causes of mental
 health problems in,
 227*box*16.1, 227–228,
 234*box*
- psychosis in, 228, 229
- referrals to health services in,
 229, 233–234
- serotonin syndrome, 230
- suicide risk in, 231–234,
 234*box*
- empathy
 in CBT, 431
 in counselling, 426–427
 in depression assessment
 and management,
 449–450*box*30.2
 diagnoses enhanced by,
 17–18
 toward drug abusers, 241,
 247, 248*box*
 toward eating disorder
 patients, 270
 in interviewing,
 449–450*box*30.2
 lack of, in prisoners/
 offenders, 344*box*24.1
 medically unexplained
 symptoms and, 26
 in motivational interviewing,
 426*box*29.3
 NICE guidelines on, 40
 as patient priority, 43,
 49–50*box*
 toward refugees, 321
 in suicide mitigation, 108–110
 in therapeutic alliances,
 34*box*3.1
 for torture victims, 315–316
- epidemiology (general)
 of anxiety, 125–126
 of asylum seekers'/refugees'
 mental health
 problems, 311
 of child and adolescent
 mental problems, 200
 of dementia, 163–164
 of depression, 74, 89–90,
 158–159
 of eating disorders, 268–269
- epidemiology of, 164*t*11.2
 of perinatal health problems,
 186–187
 of psychotic disorders,
 214–215
 of sexual problems, 329–330
- epidemiology of mental illness
 overview, 12, 21*box*1.2
 burden of psychiatric
 disorders and, 16–17
 data collection in, 14
 definitions and
 characteristics, 12, 21*box*
 international perspectives
 of, 20
 key points of, 21*box*
 in LAMI countries, 20
 mental illness within the
 community and, 15–16
 MUS and, 19–20
 pathways to psychiatric care
 and, 13–14
 prevalence vs. need and, 20
 psychiatric disorder
 assessment and definition
 in, 14–15
 of psychiatric disorder in
 PCMH attenders, 17–19,
 18*t*2.1
 treatment availability and
 effectiveness rates and, 20
- epilepsy, 61, 202, 261*box*18.5
- Estonia, 374, 375
- ethnic minorities
 overview, 300–307
 access to mental health care
 for, 304–305, 390
 antidepressant medication
 less acceptable to, 303
 barriers to PCMH
 intervention for, 303,
 304–305, 305*box*21.2,
 307*box*
 in case studies, 302
 cultural issues of, 300, 301,
 303–305, 306
 depression in, 29–30, 301,
 303–304
 in exile, 311, 312, 314,
 317–318, 322*box*
 factors for mental health
 problems in, 301–305,
 302*box*21.1
 health interventions for, 357
 health services underused by,
 303, 304–305

- improvement in treatment outcomes for, 307*box*
- inverse care law and, 389
- key points of PCMH for, 307*box*
- lack of treatment provision for, 301
- lack of treatment-seeking among, 301
- mental illness as stigma among, 303
- mental illness rates among, 300–304
- mental illness undetected in, 300
- migration among, increasing, 300
- multidimensional aspects of, 300
- PCMH education and advocacy for, 307
- PCMH issues in mental illness care for, 303–304
- suicide in, 231–232*box*16.2
- supernatural treatments sought by, 301, 303
- treatments unacceptable to, 301
- Eurobarometer study, 41–42, 48–49
- Eurocommunication study, 46
- European Union (EU), 127, 260, 374, 375
- exercise as therapy
- alcohol use problems and, 257
 - anxiety and, 93, 425, 434
 - in case studies, 258, 271–272*t*19.2, 475, 476–477
 - depression and, 425, 434
 - graded exercise therapy, 146–148, 446
 - LTCs and, 178
 - NICE guidelines on, 424–425
 - obesity and, 290
 - for older people, 161
 - perinatal mental health problems and, 194–195
 - in physiological therapies, 424*box*29.2
 - severe mental illness and, 291
 - sexual problems and, 333–334, 335, 337
- exile. *See* asylum seekers and refugees
- Expert Patient Programme, 48
- exposure therapy, 132–133, 424*box*29.2, 428
- Faris, R.E.L., 215
- Finland, 374, 375
- Five Year Forward View mandate, 49
- five-areas therapy model, 421–424, 423*fig*29.2, 428, 431, 433
- Foley, D.L., 81
- Forrester, Andrew, viii, 343–350
- France, 18*t*.1, 375
- Fry, John, 1
- Fuller, J.D., 393
- GAD. *See* generalised anxiety disorder
- Gask, Linda, viii, 1–9, 39–49, 70–82, 386–397, 401–413, 420–434, 459–469
- GBD. *See* Global Burden of Disease (GBD) study
- General Health Questionnaire (GHQ), 80
- general practitioners and mental health
- overview, 480–486
 - Balint groups for, 485
 - barriers to care accessed by, 481–482
 - burn-out among, 480, 481, 482
 - confidentiality issues among, 484
 - extent of, 480–481, 485–486
 - GPs consulting with, 485
 - medical problems undisclosed by, 481–482, 484
 - organizational issues in, 485–486
 - Practitioner Health Programme developed for, 480, 484
 - prevention of, 483
 - prognosis for, 485–486
 - providing appropriate care for, 484
 - reasons for, 480–481
 - risk factors and causes of GP health problems, 482–483*t*33.1, 485–486
 - self-referral among, 484
 - stigmatization of, 482
 - types of mental illnesses among, 480, 481, 484
 - younger age groups of, 480
- general practitioners (GPs). *See* also Royal College of General Practitioners
- core competencies for, 439–446, 440–445*t*30.1
 - emerging PCMH roles of, 1, 4–5, 35, 39
 - majority of patients seen by, 393, 459
 - in PCMH teams, 9, 375
 - preferred over specialists, 25, 374
- generalised anxiety disorder (GAD)
- CBT for, 132–133
 - characteristics of, 128–129*t*9.2
 - diagnosis of, 129
 - as disabling, 125
 - first, second and third line medication for, 133*t*9.3
 - improvement lacking in, 132
 - interventions for, 132
 - LTCs and, 177
 - perinatal, 187
 - prevalence of, 16, 126*t*9.1, 354*t*25.1
 - prognosis for, 126
 - psychological therapies for, 132–133
 - self-help therapies for, 132
 - triggers of, 128–129*t*9.2
- generalised anxiety disorder scale (GAD-7), 80, 129, 134, 177, 302, 408
- Gerada, Clare, viii, 480–486
- Geriatric Depression Scale, 177
- Germany, 6, 18*t*.1, 375
- Gerritsen, A., 311
- Gilbody, Simon, viii, 386–397, 401–413, 453–454, 464–465
- Global Burden of Disease (GBD) study, 15–17, 89–90, 97, 253, 373. *See* also *burdens of specific mental disorders*

- Goldberg, David, viii, 7, 14, 17, 18*t*.1, 21*box*, 439–456
- Goodman, R., 203–204
- Gourlay, D.L., 245
- GPs. *See* general practitioners
- Grand Challenges in Global Mental Health initiative, 55
- Greece, 18*t*.1, 374
- Guinea Bissau, 61
- Gunn, Jane, 2, 87–98
- Gureje, Oye, viii, 54–64, 70–82
- Gyani, A., 409
- habitus, 24–25, 31
- Haddad, Mark, viii, 373–381
- hallucinations
 - in alcohol dependence, 252*box*18.1
 - in case studies, 171, 226
 - delirium and, 153, 154, 227–228
 - delusions and, 171
 - in Lewy-body disease, 165–166, 169
 - in psychoses, 187, 214–215, 216, 228
 - in psychosis, 226
 - suicidal thoughts and, 112*box*8.3
- Hamilton, Fiona, viii, 251–263*box*18.6
- Hammond, J., 466
- Hart, Julian Tudor, 176
- Hawton, K., 105–106
- Health and Social Care Act (2012), 49, 361–362, 366*box*25.2
- health anxiety/illness disorder, 131
- Health for All by 2000 programme, 57, 58*box*5.2, 64
- Healy, D., 33
- Hearing Voices Network, 39–40
- help-seeking behaviours and strategies
 - barriers to, 269–270
 - clinicians' attitudes toward mental health issues and, 381*box*
 - gender issues in, 27–28, 29–30
 - GP's preferred over specialists in, 374
 - material disadvantage reducing, 27, 304
 - patients' individual experiences in, 8, 30–31
 - racial issues and, 28–30
 - somatic issues in, 29
 - suicide and, 114
 - treatment issues in, 31
 - by young people, 114
- Henderson, M., 482
- Heyman, Isobel, viii, 200–209
- Hill, Jacqueline J., viii, 270, 401–413
- Hispanic minorities, 303–304
- HIV, 163*box*11.6, 239*t*17.2, 240, 241, 278*box*20.1, 292
- HIV/AIDS, 57, 58*box*5.2, 58
- Hodges, B., 447
- holistic care
 - GPs views of, 218
 - in LAMI countries, 64
 - mental illness and, 277–278, 295*box*, 295
 - NICE recommendations for, 134
 - as patient priority, 41, 46
 - PCMH advantages in, 4
 - PCMH integration as essential to, 9
 - PCMH teams providing, 172*box*, 222*box*
- physical health problems and, 295
- Royal College of General Practitioners and, 376, 440–445*t*30.1
- as whole system
 - intervention, 180
- Holt, Richard, viii, 277–295
- Hospital Anxiety and Depression Scale (HAD), 80, 92, 93*t*7.1, 129, 177
- Hull, Martyn, viii, 236–248
- Human Development Index and Reports, 56*box*5.1
- Hungary, 375
- Huxley, P., 7, 14
- hypochondriasis, 131, 138, 159, 161–162. *See also* medically unexplained symptoms; somatic issues
- IAPT (Improving Access to Psychological Therapies) programme
 - access to mental health care improved by, 388–389, 394, 396–397, 397*box*
 - aims and features of, 14, 16, 26, 46, 388, 389
 - AMP programme in, 390
 - anxiety treatment in, 388, 389
 - attrition rates in, 388–389
 - in case study, 179*box*12.2
 - CBT in, 389
 - critiques of, 389
 - depression treatment in, 388, 389
 - as new role for PCMH, 376
 - patients' preferences expressed in, 46
 - psychological therapies in, 420
 - psychological therapy referral model and, 402–403
 - specialist integration into, 381*box*
 - stepped care and, 407–409, 410
 - unavailability of, 389, 397*box*
- iatrogenic conditions, 32, 33, 142, 144–145, 146, 147*box*10.1, 229–230
- IBA (identification and brief advice), 253–254, 260. *See also* brief intervention
- ICD-10 (*International Statistical Classification of Diseases and Related Health Problems*)
 - alcohol dependence criteria listed in, 252*box*18.1
 - limitations of, 76–77
 - as mental health classification system, 76–77
 - MUS and, 138–139
 - in perinatal settings, 186
 - subthreshold disorders and, 76
 - as WHO diagnostic/classification system, 70–72
- ICD-10-PHC (simplified version of ICD-10), 70–72, 76–77
- ICD-11 (ICD-10 revision)
 - adjustment disorder and, 88–89
 - cross-cultural validity of, 76
 - depression in, 70–72, 186
 - episode structure of, 79

- as mental health
classification system, 75, 76–77
- somatoform disorders and, 138–139
- sub-threshold disorders and, 76
- ICD-11-PHC, 77*box*6.1
- ICPC (*International Classification of Primary Care*), 72*t*6.2, 76–77, 138–139
- ICPC-2 classification system, 70–72, 76–79, 78–79*box*6.2
- identification and brief advice (IBA), 253–254, 260. *See also* brief intervention
- improving access to health care. *See* access to mental health care
- Improving Access to Psychological Therapies programme. *See* IAPT programme
- impulse control disorders, 201, 354*t*25.2
- India, 18*t*2.1, 59, 61, 62, 63, 231–232*box*16.2
- interpersonal psychotherapy (IPT), 161, 191, 192*box*13.2, 194–195
- Inventory to Diagnose Depression, 80
- inverse care law, 176–177*box*12.1, 176, 389, 397, 462–463
- Iran, 61
- Iraq, 311
- Ireland, 375
- irritable bowel syndrome, 138, 145
- Isaac, Mohan, viii, 54–64
- Italy, 18*t*2.1, 374
- James, Alison, 270
- Japan, 18*t*2.1, 378
- Johnson, Virginia, 332, 335
- Kabatt-Zinn, Jon, 432–433
- Katon, Wayne, 404
- Kegel exercises, 335
- Kendrick, Tony, viii–ix, 1–9, 87–98, 125–135, 226–234, 386–397, 459–469, 473–478
- Kessler, D., 462–463
- Khan, N., 40, 42
- King, Alys Cole, 103–119
- King, Michael, viii–ix, 327–338
- Kirkpatrick, D., 454*t*30.2
- Klinkman, Michael, viii–ix, 70–82
- Klusmann, D., 41
- Knapp, M., 118
- Korea, 375
- Kraepelin, Emil, 219
- LAMI. *See* low and middle-income countries
- Lang, Katie, viii–ix, 267–273
- Latin America, 54, 55, 301
- Latvia, 375
- Lecrubier, P., 18*t*2.1
- Lesser, A.L., 451
- Lester, Helen, viii–ix, 42, 45, 213–222, 219*box*15.3, 226–234, 251, 263*box*18.6, 294–295, 380–381
- Lewis, Barry, viii–ix, 420–434, 439–456
- Lewis, Glyn, viii–ix, 12, 21*box*1.2
- Lewy-body disease, 155–157, 163*box*11.6, 165–166, 169
- Leydon, G.M., 47
- Lobban, F., 41
- long-term physical conditions (LTCs) and mental health. *See* physical conditions (long-term) (LTCs)
- Lorig, Kate, 48
- Lovell, Karina, viii–ix, 420–434
- low and middle-income (LAMI) countries
overview, 54–64
as developing countries, 55, 59–61, 60*t*5.2
differences among, 56
health care priorities in, 57, 58*box*5.2, 60*t*5.2, 60
Health for All by 2000 programme, 57, 58*box*5.2, 64
health policy changes for, 57–59, 58*box*5.2
health systems in, 59–61
Human Development Index and, 56*box*5.1
identification criteria, 55
key points of, 65*box*
MDGs for, 57–59, 58*box*5.2
- mental health burdens in, 59
- mental health initiatives
absent in MGDs for, 59
- mental health teaching in, 454, 455
- mental-disorder neglect in, 54
- mortality in, 56, 57, 58, 59
- Movement for Global Mental Health and, 62
- PCMH in, 54, 55, 61–64
- populations per doctor in, 60
- SDGs for, 58*box*5.2, 59
- secondary care in, 55, 64
- service and training packages for, 54–55
- specialist services in, 60, 64
- sustainable development goals for, 59
- universal health coverage and, 58*box*5.2, 59
- World Bank classification of, 56*t*5.1
- Luxembourg, 375
- major depression. *See* depression (major)
- malaria, 57
- Malta, 375
- Manchester (UK), 18*t*2.1, 304
- Masters, William, 332, 335
- maternal health issues. *See* perinatal mental health problems
- Mauss, M., 24–25
- MDD (major depressive disorder subscale), 70–72, 79, 80
- MDMA (ecstasy). *See* drug use disorders; psychotic disorders
- Meadows, G.N., 406
- medicalization, 20, 32, 42, 62
- medically unexplained symptoms (MUS). *See also* physical conditions (long-term) (LTCs); somatic issues
overview, 138–148
aetiology of, 142–143
anxiety and, 19–20
in case studies, 139–140, 142, 144–145
in children and adolescents, 202

- (MUS) (cont.)
- chronic fatigue syndrome, 19, 138
 - classification of, 138–140
 - clinicians' management of, 147*box*10.1
 - collaborative care for, 146
 - consultation with patients and, 144–145
 - definitions and characteristics, 138, 202
 - empathy and, 26
 - Extended Reattribution and Management model for, 146
 - healthcare providers impact on, 142
 - iatrogenesis in, 143, 144–145, 146, 147*box*10.1
 - identification of risk factors for, 143
 - irritable bowel syndrome, 138
 - key points of, 148*box*
 - maintaining factors in, 142
 - management of patients with, 147*box*10.1
 - mild, 144
 - moderate, 145–146
 - neurophysiological changes and, 142–143
 - patient management, 144*fig*10.4, 144–146
 - persistent, 144–145
 - pharmacological treatments for, 146
 - physical conditions and, 144–145
 - physical management of, 147*box*10.1
 - predisposing factors in, 142
 - prevalence of, 141*fig*10.2
 - psychiatric disorders associated with, 19
 - psychological management of, 147*box*10.1
 - psychopharmacological management of, 147*box*10.1
 - self-help for, 145
 - severe/chronic, 146–148, 147*box*10.1
 - terminologies describing, 138
 - triggers of, 142
 - uncertainty levels in treatment of, 148
 - medication. *See* antidepressant medications; benzodiazepines; child and adolescent mental health problems; depression; drug dependence; education and training model; general practitioners; patients/service users; SSRIs
 - mental health. *See* general practitioners and mental health; mental health research in primary care; perinatal mental health problems; physical conditions (long-term) (LTCs); primary care mental health (PCMH); prison populations and offenders; public mental health; sociological views of mental health and illness; teaching and learning about mental health
 - mental health defined, 3, 28, 356–357
 - Mental Health Expert Committee of the World Health Organization, 54
 - Mental Health First Aid Lite training sessions, 45
 - mental health Gap Action Programme. *See* mhGAP
 - mental health policy, 6–7
 - mental health research in primary care overview, 459–469
 - case-control studies in, 462
 - clinical practice observations in, 463
 - cohort studies in, 462
 - constant comparison studies in, 465
 - controlled trials in, 463–464
 - cross-sectional studies in, 462
 - disorder study descriptions in, 461–463
 - ethnographic studies in, 466
 - evaluation of offers to participate in, 460, 461*box*31.2
 - factors affecting practitioner involvement in, 459–460
 - grounded theory studies in, 465
 - key points of, 470*box*
 - longitudinal studies of, 462–463
 - Michael Moore's career trajectory in, 468–469
 - mixed method research in, 466–467
 - vs. mortality, 356–357
 - the need for, 459, 470*box*
 - on PCMH clinicians, 478
 - PCMH practitioners' development and delivering, 467–468, 470*box*
 - poverty and, 462
 - qualitative studies in, 465–467, 470*box*
 - quantitative designs in, 461–465, 470*box*
 - questions to consider for participation in, 460–461*box*31.2
 - randomised controlled trials in, 459*box*31.1
 - recall bias in, 462
 - research networks' roles in, 467, 470*box*
 - respondent validation in, 465
 - services provision determined by, 459
 - sociological factors in, 462
 - surveys in, 461
 - systematic reviews in, 464–465
 - triangulation of data in, 465
 - mental illness. *See* specific mental health problems
 - mental illness defined, 70
 - Mercer, Stewart W., ix, 175–181*box*12.3
 - mhGAP (mental health Gap Action Programme), 54, 62, 64, 79, 81
 - Millennium Development Goals (MDG), 57–59, 58*box*5.2
 - mindfulness-based therapy aims of, 432–433

- in case study, 134
as CBT, 132–133, 424*box*29.2, 432
core practice of, 433*box*29.6
effectiveness of, 96–97, 433
as first line of treatment, 135*box*
Mindfulness-Based Stress Reduction, 180
in wellbeing, 361, 483
as whole system intervention, 180
Mitchell, A.J., 464–465
models of service. *See* collaborative care; consultation-liaison model; education and training model; pathways to care model; psychological therapy referral model; stepped care
Moore, Michael, ix, 459–469
morbidity. *See also* comorbidity; multimorbidity
alcohol use problems and, 253
depression and, 74
drug use disorders and, 245
extent of, in mental illness, 6, 12
LTCs and, 16–17, 175
patients' needs and system responses to, 43
Psychiatric Morbidity Surveys, 14
psychotic disorders and, 218, 221
self-harm and, 103, 118, 201
suicide and, 103, 118, 201
surveys on, 12, 14, 16
motivational interviewing, 422*t*29.1, 434*box*, 434
Multidimensional Poverty Index, 56*box*5.1
multimorbidity. *See also* comorbidity; morbidity
autism spectrum and, 203
collaborative care and, 178
depression and, 175–176
inverse care law and, 181*box*
LTCs and, 175–176, 177–178, 179, 181*box*
in older people, 175–176
pathology overlaps and, 74–76
single disease focus vs., 2
socioeconomic status and, 175, 176–177*box*12.1, 181*box*
whole systems interventions for, 180
MUS. *See* medically unexplained symptoms
National Comorbidity Survey, 14
National Confidential Inquiry, 108, 114
National Institute for Health and Clinical Excellence. *See* NICE
Nazareth, Irwin, ix, 213–222
Nepal, 61
Netherlands
anxiety disorders in, 125
ICD-10 used in, 70–72
nurse-led clinics in, 375
nurses trained for specialist roles in, 375
psychiatric disorder prevalence in, 18*t*2.1
refugees in, 311
schizophrenia rates in, 300–301
stepped RTCs in, 408, 411
New South Wales, 289–290
New Zealand, 75–76, 98, 126*t*9.1, 127, 216–217
Nicaragua, 61
NICE (National Institute for Health and Clinical Excellence) guidelines
for access to mental health care, 387–388*box*27.1
on alcohol dependence, 261*box*18.5
for antidepressants, 94–95
for anxiety disorders, 134
for assessment following self-harm, 107, 108
CBT practitioner shortages and, 46
for childhood depression and anxiety, 203–204, 205–207
for depression management, 80, 92, 463, 473–474
development of, 40, 134
for eating disorder screening, 270
for exercise as therapy, 424–425
for GAD, 131–134
for holistic care, 134
Lester Positive Cardiometabolic Health tool endorsed by, 294–295
for LTC comorbidity, 177
Moore as contributor to, 469
for patients/service users, 40
for PCMH services for mental illness, 293, 294–295
for postnatal depression medication, 193
for public mental health, 360
specialist mental services, 278–279
on SSRI's, 94–95
for stepped care, 91, 409, 420
Nigeria, 18*t*2.1
Norway, 218, 300–301
nurses
brief intervention training of, 258–259
in case studies, 154, 170, 171, 176–177*box*12.1, 179*box*12.2, 226, 258, 349
clinics led by, 375
in collaborative care, 30, 179*box*12.2, 379
as communicators, 41–42
confidence issues of, 379, 380
depressed patients supported by, 378
health centres run by, 60
Lester's proposals for, 294–295
mental health training of, 376, 377–378
older people treated by, 160
patients' preferences for, 41–42
in patients' questionnaire evaluating, 44*box*4.2
PCMH obstacles to, 379
in PCMH teams, 2, 5, 46, 375, 381*box*
PCMH training requirements of, 376
physical illness monitoring by, 380
in prison PCMH teams, 348, 349

- nurses (cont.)
 SMI patients and, 391–392, 406, 455
 SMI patients' referrals too, 454–455
 specialist development encouraged for, 5
 therapies administered by, 93–94, 132–133, 376
 training in specialist care, 375, 377–378
 training requirements for, 376
 working in prisons, 347
 working with SMI patients, 391–392
 Nutt, David, 238
- obesity. *See also* eating disorders
 cardiovascular disease and, 281*t*20.3, 289
 medications prescribed for, 287
 mental illness and, 279–280, 285*fig*20.2, 288–290, 295*box*
 prevalence of, 289
 psychotic disorders and, 218
 pulmonary disorders and, 292
 schizophrenia and, 278*box*20.1, 289
- obsessive-compulsive disorder (OCD)
 characteristics of, 128–129*t*9.2
 diagnosis of, 130
 as disabling, 125
 first, second and third line medication for, 133*t*9.3
 perinatal, 187
 prevalence of, 126*t*9.1, 354*t*25.1
 in prisoners/offenders, 343, 345
 triggers of, 128–129*t*9.2
- Ödegaard, O., 301
- OECD nations, 373–374, 375, 377, 379, 380
- older people (general)
 overview of medical problems in, 153, 172*box*11.8
 abbreviated mental test score for, 157*box*11.3
 access to mental health care for, 390
 as asylum seekers/refugees, 318
 collaborative care for, 172*box*
 distress among, 318
 GPs' roles in mental health of, 171
 health services underused by, 386
 holistic treatments for, 172*box*
 multimorbidity in, 175–176
 PCMH for, 106, 171, 172*box*
 recognition of symptoms in, 172*box*
- older people (delirium in)
 overview, 153–158
 antidepressants for, 156*box*11.2
 in case studies, 154, 158
 definitions and characteristics, 153
 delusions and, 153
 dementia and, 227
 vs. depression or dementia, 153*t*11.1
 diagnosis of, 154–155
 hyperactive, 154
 hypoactive, 154
 management principles for, 155–157, 158
 mental capacities and, 157–158
 mixed, 154
 Parkinson's disease and, 155–157
 physical health problems and, 154, 155*box*
 precipitants of, 156*box*11.2
 presentation of, 153–154
 referred to mental health services, 158
 risk factors for, 155*box*11.1
 triggers of, 154
- older people (delusions in), 153, 154, 160, 170–171
- older people (dementia in)
 overview, 163–170
 Alzheimer's disease and, 163*box*11.6, 163–164, 165, 166, 168, 169
 cardiovascular disease and, 163–164
 in case studies, 163, 169
 causes of, 163*box*11.6
 cognitive testing and screening for, 166, 167*t*11.3, 169
 definitions and characteristics, 163, 165–166
 delirium and, 227
 vs. delirium or depression, 153*t*11.1
 delusions and, 153, 154, 170–171
 depression and, 159, 168
 diagnosis of, 164, 166
 driving and, 167
 drug treatments for, 165–166, 168–169
 epidemiology of, 163–164, 164*t*11.2
 frontotemporal dementia and, 166
 GPs' roles in managing, 169
 imaging of, 170
 investigations of, 167
 Korsakoff's psychosis and, 166
 Lewy-body disease and, 155–157, 163*box*11.6, 165–166, 169
 management of, 168
 mild cognitive impairment in, 170
 mixed dementia and, 165
 Parkinson's disease and, 155*box*11.1, 163, 165–166, 169
 physical health problems and, 169
 prevalence of, 354*t*25.1
 prevalence of, in the future, 16
 psychological therapies for, 168
 risk assessment for, 164–165, 165*box*11.7, 169
 testing and screening for, 166, 167*t*11.3, 169
 vascular dementia and, 163*box*11.6, 164, 165, 169, 170, 171
- older people (depression in)
 overview, 158–162
 antidepressants for, 28, 159, 160–161, 162
 anxiety combined with, 159, 161

- bereavement and, 159
 in case studies, 159, 161–162
 clinical evaluation of, 160
 collaborative care for, 160
 comorbidity and, 159
 vs. delirium or dementia, 153*t*11.1
 dementia and, 159, 168
 diagnosis of, 159
 epidemiology of, 158–159
 family relations and, 161
 Geriatric Depression Scale for, 177
 intervention economics of, 362*t*25.6
 management principles for, 160
 PCMH screening for, 160*box*11.4
 physical activity and, 161
 physical health problems and, 159, 160*box*11.4, 162, 171, 172*box*11.8
 prevention of, 359
 psychological interventions for, 161
 referrals to health services for, 162*box*11.5, 162
 risk factors for, 160*box*11.4
 specialist care for, 162*box*11.5, 162
 sub-syndromal symptoms, 158–159
- O'Neill, Siobhan, ix, 103–119
- on-line therapy, 46
- oppositional defiant disorder, 201–202, 203, 206*t*14.2
- Osborn, D.J.P., 462
- Pakistani ethnic minorities, 40, 301, 304, 306, 466
- Panagioti, M., 485
- panic attacks, 125, 129–130, 216, 244, 312
- panic disorder
 in acute mental health emergencies, 228
 agoraphobia and, 129–130
 benzodiazepines for, 133–134
 CBT for, 132–133
 diagnosis of, 129–130
 first, second and third line medication for, 133*t*9.3
 management of, 131
 panic attacks vs., 129–130
- perinatal, 187
 prevalence of, 125, 126*t*9.1
 prognosis for, 126
 triggers of, 128*t*9.2–129*t*9.2
- Parkinson's disease
 in case study, 423
 delirium and, 155*box*11.1
 dementia and, 155–157, 163, 165–166, 169
 pathways to care model, 7, 13–14, 402
- Patient Health Questionnaires. *See* PHQs
- Patient Participation Groups (PPGs), 49
- patient reported outcome measures (PROMs), 92, 129
- patient-centred therapies and services
 access to mental health care and, 434
 authors' preferences for, 3
 in case study, 424–425
 collaborative care and, 404, 405, 406
 costs of, 403
 in financially deprived areas, 176
 future developments for, 413
 mental health applications of, 440–445*t*30.1
 other therapies and, 403
 patients' preferences for, 402
- patients/service users. *See also* stigmatization
 overview, 39–49
 choice as component in involvement of, 48–49
 collaborating in recovery, 46, 48–49
 community-based services preferred by, 47–48
 confidentiality as priority of, 46
 continuity of care as priority of, 41–42, 45, 49–50*box*, 218–219
 defined, 8–9, 39
 demographics of higher health-care involvement, 49–50*box*
 depression experiences described by, 40–41, 42–43
 expertise of, 40, 48
- GPs rated by, 43
 initiating PCMH, 18–19
 involved in mental health care, 39–40
 key points of, 49–50*box*
 lack of control sensed by, 42
 medication concerns of, 47
 mental health care perspectives of, 40
 needs and expectations of, 45–46
 optimism as a priority among, 219–220, 221–222
 patients' comfort levels with vs. doctors, 41–42
 PCMH as viewed by, 42–44
 primary care environment for, 45
 priorities as reported by, 43*box*4.1
 psychological therapies for, 46–47
 psychologically informed environment for, 45
 with psychotic disorders, 41, 218–220, 221–222
 public involvement and, 49
 questionnaire in experiences of, 44*box*4.2
 as secondary care research focus, 49–50*box*
 stigmatization of, 19–20, 25, 27, 42
 stress-related needs of, 4, 43, 49–50*box*
 trust as priority of, 34*box*3.1, 40, 46
- PCMH. *See* primary care mental health
- Pendleton, D., 451
- performance anxiety, 133–134
- perinatal mental health problems (general)
 overview, 185–196
 alcohol use problems and, 187
 antenatal depression, 186–187
 baby blues, 187, 196*box*
 bipolar disorder and, 185, 189, 194
 burdens of, 195
 in case study, 190
 children affected by, 185, 192*box*13.2
 classification of, 186

- perinatal mental (cont.)
 depression history as risk factor for, 190, 194
 detection and diagnosis of, 190
 domestic violence and, 185
 drug misuse and, 187
 eating disorders and, 185
 epidemiology of, 186–187
 identification of, 185, 196*box*
 key points of, 196*box*
 management of, 191
 maternal mortality rates and, 185
 medication for, 185, 193, 196*box*
 midwife training in, 195
 organization of care for, 195–196
 in parents, 185, 358–359
 PCMH teams roles in training, 196*box*
 prediction of, 188–190
 during pregnancy, 358
 psychological approaches to, 196*box*
 psychosis and, 185, 187, 188, 189, 194, 196*box*
 PTSD and, 185, 193
 risk factors for, 189*box*13.1
 RTCs for, 191
 schizophrenia and, 189, 194
 screening for, 188–189, 196*box*
 social support vs., 185
- perinatal mental health problems (postnatal depression)
 antidepressant medication for, 186, 194*box*13.3
 in Black Caribbean immigrants, 301
 burdens of, 195
 in case studies, 190
 children affected by, 185, 192*box*13.2
 cultural expressions of, 188
 in ethnic minorities, 301
 medication for, 193–194, 194*box*13.3
 medication risks in, 193
 onset of, 188
 prevalence of, 185, 187, 188, 196*box*
 prevention of, 185
- psychological approaches to, 191
 PTSD and, 186–187, 193
 risk factors for, 189*box*13.1
 in South Asian women, 29–30
 symptoms of, 190
 treatments of, 192*box*13.2
- personality disorders
 access to mental health care lacking for, 393–394
 borderline personality disorder, 72, 343
 definitions and characteristics of, 72, 228
 life expectancy reduced by, 355*t*25.4
 mortality and, 279*t*20.1
 in prisoners/offenders, 343
- person-centred therapy model, 421–424, 423*fig*29.2, 426–427, 434*box*
- Pescosolido, B.A., 30–31
- Peveler, Robert, ix, 1–9, 19, 277–295, 459–469
- Philippines, 61
- phobias, 128–129*t*9.2, 130, 133–134, 354*t*25.1
- PHQs (Patient Health Questionnaires)
 in the Doncaster/Newham studies, 408
 on depression (general), 80, 87, 92, 134, 159, 177
 on depression (major), 87, 88*box*7.1, 473–474, 475, 477
 for risk factor predictors and identification, 143*fig*10.3
 on somatic symptoms, 80, 143
 in stepped care, 408, 410
- physical conditions (long-term) (LTCs)
 overview, 175, 181*box*12.3
 bi-directionality of, 175
 burdens of, 355–356
 CARE Plus intervention for, 180
 in case studies, 176–177*box*12.1, 179*box*12.2
 Chronic Care Model for, 178
 collaborative care for, 178–179, 179*box*12.2
 comorbidity and, 175
- delirium in older people and, 154–155
 depression and, 90*box*7.2, 91, 92, 177–179, 180, 181*box*, 379
 depression in older people and, 159, 160*box*11.4, 162, 171, 172*box*
 GPs roles in management of, 179*box*12.2
 inverse care law and, 176–177*box*12.1, 176
 key points of, 181*box*
 management of, 177–180, 181*box*
 mental illness and, 73–74, 82*box*, 355–356
 mindfulness-based interventions for, 180
 morbidity and, 175
 mortality and, 16–17, 175
 multimorbidity and, 175–178, 176–177*box*12.1, 179, 181*box*
 MUS and, 138, 143, 144–145
 numbers of, vs. types of, 175
 organizational interventions for, 178–180
 psychological therapies for, 178, 422*box*29.1
 psychotic disorders and, 218, 221
 recognition and assessment of, 177
 SMI combined with, 380
 socioeconomic status and, 175, 176–177*box*12.1, 357
 somatoform disorders and, 141
 suicide and, 104, 105, 119–120*box*, 232
 whole systems interventions for, 180, 181*box*
- physical health of people with mental illness
 overview, 277–295
 cardiovascular disease affecting, 17, 280, 281*t*20.3, 285
 in case study, 277
 community-based care for, 293
 comorbidity and, 277–278
 diabetes affecting, 281*t*20.3, 285*fig*20.2, 286*box*20.2, 289

- dyslipidaemia affecting, 280, 281*t*20.3
- HIV affecting, 292
- holistic care for, 277–279
- hyperprolactinaemia affecting, 290*box*20.3, 290
- hypertension affecting, 281, 285
- life expectancy and, 279*t*20.2
- lithium treatments for, 293
- mortality and, 279*t*20.1, 280*fig*20.1
- obesity affecting, 281*t*20.3
- osteoporosis affecting, 290*box*20.3, 291*t*20.5, 291
- PCMH reviews for, 293–295, 295*box*
- programme accessibility for, 288
- pulminarity disorders and, 292
- risk assessment models for, 282
- screening, 283–284*t*20.4
- smoking affecting, 281*t*20.3, 282
- specialist services for, 293
- statin treatments and, 282
- weight changes and, 287, 288, 289–290
- weight changes in, 287*fig*20.3
- PICO treatment approach, 476*box*32.1, 476–478, 479*box*
- Pilgrim, David, ix, 24–36
- Pincus, H.A., 76
- Poland, 374, 375
- Portugal, 375
- postnatal/postpartum depression. *See* perinatal mental health problems (postnatal depression)
- post-traumatic stress disorder (PTSD)
- antidepressant medication for, 193
- in asylum seekers/refugees, 311, 313
- characteristics of, 128–129*t*9.2
- diagnosis of, 131
- as disabling, 125
- eye-movement desensitization for, 133–134
- first, second and third line medication for, 133*t*9.3
- GPs with symptoms of, 484
- perinatal, 186–187
- prenatal, 186–187, 193
- prevalence of, 16, 126*t*9.1, 354*t*25.1
- in prisoners/offenders, 343, 345
- triggers of, 128–129*t*9.2
- poverty
- asylum seekers and refugees, 311, 313, 322*box*
- common mental health problems and, 63–64
- depression (general) and, 286
- drug use disorders and, 240
- mental health research in primary care and, 462
- PCMH and, 57, 59, 63–64, 98
- SDGs addressing, 58*box*5.2
- PPGs (Patient Participation Groups), 49
- primary care mental health (PCMH). *See also* anxiety; cognitive behaviour therapy; depression; emergencies in primary care; low and middle-income (LAMI) countries; mental health research in primary care; nurses; patients/service users; psychotic disorders; public mental health; sociological views of mental health and illness
- overview, 1–9
- advantages of, 4–5
- aims/definitions/features of, 1–2, 381, 401–402
- disadvantages of, 4–5
- integrated into health care systems, 7, 8*box*1.1, 9, 54, 61, 62, 374, 381
- key points of, 9*box*
- as primary provider of mental healthcare, 36*box*, 42, 402, 466
- primary care mental health teams. *See also* nurses
- overview, 373–381
- anxiety disorder management by, 376–377
- anxiety management by, 376–377
- attitudes in, toward mental health problems, 377–378
- basic functions of, 373
- care enhancement by, 377–379
- CBT offered by, 376
- clinicians' attitudes toward mental health issues and, 378, 381*box*
- collaborative care and, 373
- common mental problems addressed by, 376–377
- comprehensive services provided by, 375
- depression management by, 376–377
- enhanced roles of, 381*box*
- focus on, 9
- GP integration into, 375
- GP practice as separate from, 375
- GP training in, 375
- GPs in, 5, 9
- holistic care provided by, 172*box*, 222*box*
- IAPT programme and, 376
- integrated care coordination by, 381
- IT resources available to, 380–381
- key points of, 381*box*
- knowledge and attitudes of, 377–378
- mental health skills required in, 381*box*
- mental illness outcome disparities and, 373–374
- new roles for, 376
- older peoples' care provided by, 171
- patients/service users of, 8–9
- practitioners in, 375
- in prenatal mental health, 196*box*
- questionnaires submitted to, 375, 378
- SMI care provided by, 379–381, 381*box*
- as stepped care providers, 8
- stigmatization addressed by, 4, 374, 381*box*, 381
- structure of, 5*fig*1.1
- suicide prevention by, 118

- primary care (cont.)
 survey responses
 concerning, 374*fig*26.1
- Primary Care Screener for Affective Disorder (PC-SAD), 80
- primary-care/specialist care interface
 overview, 7
 access to, 393–395
 care pathway restructuring and, 394, 397*box*
 challenges of, 9*box*
 in collaborative care, 393, 396, 397*box*
 common mental health problems and, 8
 communication improvement in, 394–395, 397*box*
 demand management in, 394–395
 in PCMH, 393–395
 traditional referrals in, 393–394
- PRIME-MD schedule, 80
- prison populations and offenders
 overview, 343–350
 anxiety among, 343, 344, 345
 assessment of, 345, 346*box*24.2
 in case studies, 347, 349
 categories of, 343
 community care for, 346, 350*box*
 comorbidity in, 343
 depression in, 343, 344*box*24.1, 345
 engagement with, 344–345
 fit notes and, 348
 health care workers' safety among, 347
 IAPT treatment for, 344
 key points about, 350*box*
 medications prescribed for, 347–348
 mental health and social problems facing, 343–344
 mental problems presented by, 344*box*24.1
 PCMH as main care provider for, 344
 personalised care for, 346–347
- psychological therapies
 for, 348
- referrals to health services
 for, 349
- rising numbers of, 343, 350*box*
- service improvements for, 348–349
- specialist care for, 344
- substance misuse in, 343
- suicide in, 231–232*box*16.2
- talking therapies for, 348
- transitioning to the community, 350*box*
- treatment options for, 346–348
- women as, 343–344, 349
- problem-solving therapy
 access to, 98*box*7.4
 as brief intervention therapy, 427–428, 434
 for depression, 161, 427–428, 434, 446
 effectiveness of, 132–133, 434*box*
 seven-stage approach to, 428*box*29.4
 vs. solution-focused therapy, 119
 stepped care and, 408
- Prochaska, J.O., 425–426
- Psychiatric Diagnostic Screening Questionnaire (PDSQ), 80
- Psychiatric Morbidity Surveys, 14
- psychiatrists
 child psychiatrists, 207
 community treatment orders issued by, 234
 in consultation-liaison model, 396
 cultural issues respected by, 63
 GP's and, 25, 32, 35, 374, 378, 394–395, 447, 456*box*, 467–468
 medication prescribed by, 4, 32, 218, 230, 395
 as old-age specialists, 167, 168, 171
 in PCMH teams, 5
 PCMH teams working with, 375, 396
 referrals to, in the US, 14
- psychodynamic therapy, 422*t*29.1
- psychological therapies
 overview, 420–434
 access to, 420
 aims of, 420
 for alcohol use problems, 422*box*29.1
 for anxiety disorders, 422*box*29.1, 433–434
 in case studies, 423, 424–425, 431
 CBT and, 420, 434
 computer-based CBT in, 424*box*29.2
 for depression, 433–434, 449–450*box*30.2
 for drug use problems, 422*box*29.1
 as first line of treatment, 135*box*
 IAPT access to, 420
 intensity levels of, 406–407
 for LTCs, 422*box*29.1, 434*box*
 for MUS, 422*box*29.1
 for perinatal mental health problems, 422*box*29.1
 referral to specialist services, 434*box*
 self-help therapies in, 424–425, 434
 skills required for, 433–434, 447, 449–450*box*30.2
 for somatization issues, 422*box*29.1
 in stepped care, 406–408, 409, 410–413
 for stress/distress, 420, 422*box*29.1
 teaching in, 446
 types of, 421, 422*t*29.1, 424–426, 446
 women's reluctance regarding, 386
- psychological therapy referral model, 402–403, 406
- psychotic disorders. *See also* antipsychotic medications; perinatal mental health problems (psychosis)
 overview, 213–222
 access to mental health care for patients with, 391
 acute, 214*box*15.1, 228

- Aetiology and Ethnicity in Schizophrenia and Other Psychoses (AESOP) study, 215
- assessment of, 14
- bipolar disorder among, 214*box*15.1
- burdens of, 213, 214*box*15.1
- cannabis use and, 215, 216, 240
- cardiovascular disease and, 218, 221
- in case studies, 213
- CBT for, 220–221
- challenges posed by, 213, 214*box*15.1
- in children and adolescents, 217
- chronic, 214*box*15.1, 217–220, 219*box*15.3
- CMHT services for, 217, 226
- cocaine use and, 227*box*16.1
- cost savings for, 364
- definitions and characteristics, 213–214, 216
- detection of, 216*box*15.2, 216, 222*box*
- diagnosis of, 220, 221–222, 222*box*
- early intervention for, 220
- Early Psychosis Declaration, 217
- ecstasy use and, 227*box*16.1
- epidemiology of, 214–215
- family histories of, 344*box*24.1
- first episode, 215, 217
- ICD-10 classifications of, 214*box*15.1
- key points of, 222*box*
- Korsakoff's psychosis, 166
- management of, 216–219
- medical education and, 446
- mortality and, 218, 221
- National Early Intervention Programme, 217
- obesity and, 218
- patients descriptions of, 41
- pay-for-performance schemes for, 221
- PCMH adequacy for, 219*box*15.3
- PCMH diagnosis of, 221–222
- PCMH providers' improvements of care for, 220*box*15.4
- PCMH treatment of, going forward, 220–221
- PCMH viewed by patients with, 218–219, 219*box*15.3
- post partum, 187
- presentation of, in PCMH, 215, 219*box*15.3
- in prisoners/offenders, 349
- recovery from, 219–220
- referrals to health services for, 215, 216, 217
- risk factors for, 215
- schizophrenia among, 213, 214, 217
- secondary care for, 34
- self-referral for treatment of, 14
- smoking and, 281*t*20.3
- specialist care of, 12
- stigmatization of, 31
- stress and, 41
- suicide among, 484
- symptoms of, 216*box*15.2
- traditional (cultural) healing and, 63
- traditional medical approaches to, 63
- untreated, 215
- venues of treatment for, 12, 14
- weight changes and, 289–290
- PTSD. *See* post-traumatic stress disorder
- public mental health overview, 353–365
- adult mental disorders and, 354*t*25.1
- burdens of, 355*t*25.4, 361
- cardiovascular disease and, 357, 358
- child and adolescent mental health problems and, 354*t*25.1, 357
- cost effective interventions to promote, 363*t*25.7
- ethnic minority at risk in, 357
- factors promoting, 357–358
- intervention economics of, 361, 362*t*25.6, 365–366*box*
- intervention gaps addressed by PCMH, 364–365
- interventions in, 358–365
- Joint Health and Wellbeing Strategies for, 49, 361–362, 366*box*25.2
- key points of, 365–366*box*
- life expectancy reduction and, 355*t*25.4
- mental disorder impact on, 353–356
- mental disorder prevalence and, 354*t*25.1
- mental disorder prevention, 358–360
- mental disorder starting ages and, 354*t*25.2
- mental wellbeing and, 356–357, 360–361, 362*t*25.6, 363*t*25.7
- mindfulness-based interventions for, 361
- physical illness and, 355–358, 360
- pregnancy issues in, 358–360
- risk factors to, 357, 365
- self harm and, 355*t*25.3, 356*t*25.5, 365–366*box*
- socioeconomic status and, 357, 359, 360
- suicide and, 356*t*25.5
- Quality and Outcomes Framework (QOF) for alcohol use problems, 254
- depression/severity measurements in, 80
- devolution in, 294*n*1
- financial incentives for PCMH and, 259, 392–393
- hospital admissions and, 392–393
- mental illness reviews and, 294
- morbidity issues in, 2
- PCMH care for alcohol use problems and, 259
- PCMH care for psychosis issues and, 221
- PCMH education and, 6
- for physical illness, 277
- risk factors identification and, 104
- SMI patients in, 392–393
- racial issues. *See* African-Caribbean ethnic minorities; Black populations; ethnic minorities

- randomised controlled trials.
See RTCs
- RCGP. See Royal College of General Practitioners
- refugees. See asylum seekers and refugees
- Reilly, S., 391
- research in PCMH. See mental health research in primary care
- Richards, David A., ix, 388, 401–413
- Robinson, Louise, ix, 153–172*box*11.8
- Rogers, Anne, ix, 24–36
- Rosendal, Marianne, ix, 138–148
- Royal College of General Practitioners (RCGP), 195, 376, 439, 440–445*t*30.1, 485
- RTCs (randomised controlled trials)
analysis revealing flaws in, 466
barriers to clinician participation in, 459*box*31.1
for major depression, 473–474
research in primary care and, 459–460
in stepped care, 408–409
in treatment decisions, 473–474, 475
treatment effectiveness determined by, 464
treatment efficacy determined by, 463–464
- Russia, 97
- Salmon, P., 465–466
- Scandinavia, 216–217
- schizophrenia. See also psychotic disorders
access to mental health care for patients with, 391
burdens of, 17
cardiovascular disease and, 281*t*20.3
in case studies, 226, 277
collaborative care for patients with, 405–406
comorbidity and, 277–278, 278*box*20.1
cost savings for, 364
delusions and, 170
as dementia praecox, 219
disabling nature of, 17
dyslipidaemia and, 280–281
in ethnic minorities, 300–301
Initiative to Reduce the Impact of Schizophrenia, 217
life expectancy and, 279*t*20.2, 355*t*25.4
medication for, 193, 194
mortality and, 277, 279*t*20.1, 280*fig*20.1
National Audit of Schizophrenia, 294
obesity and, 278*box*20.1, 289
patients' descriptions of, 41
PC vs. specialist interests in, 447
PCMH and, 3–4, 14
perinatal mental health problems and, 194
prevalence of, 15–16
as puerperal risk factor, 189
QOF and, 294, 393
secondary care for, 12
smoking and, 218, 281*t*20.3
specialist care and, 3–4
as suicide risk factor, 231–232*box*16.2
weight changes and, 287, 288
- Schmidt, Ulrike, ix–x, 267–273
- SCOFF questionnaire, 270–271
- Scotland, 175, 236, 277, 294*n*1, 377–378, 395
- Scott, S., 203–204
- SDGs (Sustainable Development Goals), 58*box*5.2, 59, 64
- self-harm
as addictive, 105–106
anxiety disorders and, 134
assessment of, 105–106
causes of, 104, 105–106
in children and adolescents, 201
in depression assessment and management, 449–450*box*30.2
disease burden of, 353
emergency care necessitated by, 103
emotional disorders and, 355*t*25.3
in ethnic minorities, 301
in female prisoners, 343
interventions for, 106, 117–118, 360
morbidity and, 103, 201
mortality from, 103, 107*box*8.1
non-suicidal, 106*fig*8.2, 106
in older people, 160, 161–162
prevalence of, 16
in prisoners/offenders, 345
rates of, increasing, 16
repeated, 105–106, 107*box*8.1
safety plans for, 117
stress and, 103, 105–106
suicide and, 103–104, 105–106, 106*fig*8.2, 107*box*8.1, 112*box*8.3
in young people, 114, 355*t*25.3
- self-help therapies
advocated, 48–49
for asylum seekers/refugees, 333–334
behavioural activation and, 424–425
bibliotherapy and, 425
bibliotherapy for, 433–434
brief intervention in, 425–426, 427–428, 434*box*
in case study, 424–425
CBT and, 424
counselling in, 426–427, 434*box*
for depression, 93–94, 98*box*, 204–205, 406–407, 410, 424–425
effectiveness of, 425
for ethnic minorities, 306
exercise and, 425, 433
exposure therapy, 428
five-stage approach in, 428*box*29.4
for GAD, 132
health technologies for, 425
for LTCs, 178, 181*box*
motivational interviewing and, 425–426
for MUS, 145
as new field in PCMH, 32, 36*box*
patients' preference for, 46
prevalence of, 35
principles of, 424

- problem-solving therapy in, 427–428, 428*box*29.4
 in psychological therapies, 420
 for sexual problems, 333–334
 solution-focus therapy in, 427
 for somatic symptoms, 34*box*3.1
 stages of change in, 425, 426*fig*29.4, 426*box*29.3
 in stepped care, 406–407, 410, 412
 technology-mediated self-help therapies, 34*box*3.1
 Senegal, 61
 service users. *See* patients/service users
 severe mental illness. *See also* bipolar disorder; psychotic disorders; schizophrenia
 access to mental health care for patients with, 391–392
 collaborative care for, 397, 405–406
 comorbidity monitoring and research in, 380–381, 462
 financial incentives for treatment of, 397
 health systems lack of coordination regarding, 380
 medication prescribed for, 391–392
 nurses working with patients with, 391–392
 OCED expenditures on, 379
 optimism as a priority in patients with, 466
 PCMH as central to patients with, 379, 466
 PCMH teams' roles in treating, 379–381, 381*box*
 physical illness combined with, 380
 randomised controlled trials for, 454–455
 registers of patients with, 3, 293, 380, 391–392, 454–455
 secondary care for, 12
 as specialist health services focus, 379
 stigmatization of, 380
 sexual problems
 overview, 327–338
 anxiety about, 328, 331, 332–333, 334, 335, 336, 337, 338, 339*box*
 arousal problems, 328
 in case study, 338
 CBT for, 335–336
 comorbidity in, 331, 336
 definitions and classifications of, 327–328
 delayed ejaculation, 335–336
 depression and, 331, 334, 336
 desire problems, 328, 329*t*23.1
 detection of, 330
 as DSM-5 disorders, 336
 dyspareunia, 329*t*23.1, 337
 ejaculatory disorders, 329*t*23.1, 334–337
 epidemiology of, 329–330
 erectile disorders, 328, 329*t*23.1, 330, 331, 332–334, 338, 339*box*
 female genito-pelvic pain/penetration disorder, 328
 female orgasmic disorder, 328
 female sexual interest/arousal disorder, 328, 329*t*23.1, 336–337
 Framework for Sexual Health Improvement, 327
 help-seeking and, 327
 hyperprolactinaemia and, 290*box*20.3, 290
 investigations of, 331
 life expectancy reduced by, 360
 Male Hypoactive Sexual Desire Disorder, 328
 management of, 332–338
 medications prescribed for, 331–332, 333, 334–335, 336, 339*box*
 orgasmic disorders, 328, 329*t*23.1, 334–337
 pain issues as, 328
 PC vs. specialist interests in, 447
 performance anxiety, 332, 334
 pornography and, 331, 333–334
 premature (early) ejaculation, 327, 328, 329*t*23.1, 334–335
 prevalence of, 329*t*23.1
 questionnaires regarding, 330
 research in, 332
 screening of, 331
 sexual histories of, 330–331
 stress/distress caused by, 327, 328, 330, 338
 testosterone screening in, 331, 332–333, 335, 336–337, 339*box*
 vaginismus, 329*t*23.1, 337–338
 in women, 328, 329*t*23.1, 329, 330, 331, 332, 336–337, 339*box*
 Shafraan, Roz, ix–x, 200–209
 Sharp, Debbie, ix–x, 185–196
 Shazer, Steve de, 119
 Sheehan Disability Scale, 81
 Shepherd, Michael, 1, 6, 14
 Shiers, David, ix–x, 277–295
 Silove, D., 311, 317
 Slovakia, 375
 Slovenia, 125
 SMI. *See* severe mental illness
 Smith, H., 459–460
 smoking
 bipolar disorder and, 218, 281*t*20.3
 cannabis use and, 244
 cardiovascular disease and, 253, 281*t*20.3, 282
 dementia and, 359
 emotional disorders and, 355*t*25.3
 health risk and exclusion levels and, 355*t*25.3
 intervention economics of, 362*t*25.6
 interventions for, 356–357, 359, 360
 life expectancy reduced by, 355, 360
 osteoporosis and, 291*t*20.5
 during pregnancy, 358
 prevalence of, 354*t*25.1, 355
 as preventable cause of death, 355, 360
 psychotic disorders and, 218, 281*t*20.3
 pulminority disorders and, 292
 schizophrenia and, 218, 281*t*20.3

- social anxiety disorder (social phobia), 127, 128–129*t*9.2, 130, 133*t*9.3, 133–134
- Social Functioning Questionnaire (SFQ), 81
- sociological views of mental health and illness
- overview, 24–36
- access to health care in, 30–31, 36*box*
- age-related issues in, 28
- class issues in, 27
- conclusions regarding, 35–36
- fiscal burden issues in, 25–26
- gender issues in, 27–28
- GP's roles re-orientated in, 25
- habitus in, 24–25, 31
- help-seeking and, 8, 27–28, 29–31
- integration of patients into general population, 39
- key points of, 36*box*
- new developments in, 25–27
- PCMH's role in, 24–25
- race-related issues in, 28–30
- social inequalities and, 27, 34*box*3.1
- social networks and, 30–31, 31*n*2, 34–35
- study sources in, 24*n*1
- therapeutic alliances and, 34*box*3.1
- treatment issues in, 31–33
- solution-focused therapy, 116, 119, 422*t*29.1, 424*box*29.2, 434
- somatic issues. *See also* medically unexplained symptoms; psychological therapies
- in asylum seekers/refugees, 312, 317
- biological mechanisms in, 142
- in case study, 140–141
- vs. depression, 90
- as DSM-5 disorder, 75
- in ethnic minorities, 304
- GPs' vs. specialists' interests in, 447
- healthcare providers and, 142
- in LAMI countries, 62
- mortality and, 279*t*20.1
- multimorbidity in, 74–75
- PHQs for, 80, 143
- physical conditions combined with, 141, 447
- as physical expressions of distress, 317
- psychological therapies for, 422*box*29.1
- questionnaire measurement of, 143
- self-help therapies for, 34*box*3.1
- symptom requirements of, 138
- South Asian minorities. *See also* ethnic minorities
- AMP psychosocial intervention for, 390
- in case study, 302
- collaborative care among women among, 301
- comorbidity in, 301
- depression in women among, 29, 301
- depression undiagnosed by PCMH for, 303–304
- maternal mortality rates in, 56
- postnatal depression in, 29–30, 301
- somatic issues in women among, 29, 41
- support groups for, 302
- treatment-seeking lacking in, 301
- South East Asia, 54
- Spain, 125, 374, 375
- Spiers, J., 485
- SSRIs (selective serotonin reuptake inhibitors). *See also* antidepressant medications
- for anxiety disorders, 133
- in case study, 176–177*box*12.1
- controversies about, 47
- for depression in older people, 160–161
- effectiveness of, 194
- as first-line anxiety medication, 133*t*9.3
- long-term use of, 95–96
- NICE guidelines for, 94–95
- for postnatal depression, 193
- risks of, 33, 94–95, 128
- for sexual problems, 334
- sexual problems and, 332
- suicide and, 233
- in treatment decisions, 475
- stepped care
- overview, 401–413
- acceptability and attendance, 410–411
- aims and principles of, 8, 406, 413*box*, 420
- for anxiety, 406, 407, 412
- in care pathway restructuring, 394
- in case study, 411–413
- CBT in, 406–407
- for children and adolescents, 209–210*box*
- critiques of, 409–410, 411
- for depression, 91–97, 177, 406, 407, 408, 410, 412, 421*fig*29.1
- Doncaster/Newham demonstration sites for, 407–408, 411–413
- effectiveness of, 407–410, 413*box*
- future developments for, 413
- GAD-7 scores in trials of, 408
- IAPT guidelines for, 407–409, 410
- key points of, 413*box*
- least burden principle in, 406, 409
- LTCs and, 177, 181*box*
- monitoring of, 410
- for MUS, 144*fig*10.4
- NICE guidelines for, 409, 420
- by PCMH teams, 8
- Personalised Advantage Index, 409
- PHQ-9 scores in trials of, 408
- progressive vs. stratified, 409–410
- psychological therapies in, 406–408, 409, 410–413
- psychological therapy referral model and, 406
- RTCs for, 408–409
- self-correction in, 406
- self-help therapies in, 406–407
- service delivery issues in, 409–410, 413*box*

- stratified vs. progressive, 409–410
- stigmatization
- of alcohol use problems, 253
 - in asylum seekers/refugees, 314
 - of borderline personality disorder, 72
 - in Central/Eastern vs. Western Europe, 374–375
 - the CMHT model and, 393–394
 - of depression, 26, 474
 - of eating disorders, 269
 - of GPs experiencing mental health problems, 482
 - interventions for, 359, 360, 362*t*25.6
 - in LAMI countries, 54
 - of patients, 19–20, 25, 27, 42
 - PCMH teams addressing, 4, 374, 381*box*, 381
 - of prisoners/offenders, 344–345
 - psychotic disorders and, 31, 220
 - of self-harm, 118
 - of SMI, 380
 - suicide-related, 103–104, 110, 114
- stress and distress. *See also* post-traumatic stress disorder; psychological therapies; self-harm; sexual problems; suicidal behaviour/attempts; suicidal thoughts/ideation; suicide
- #DearDistressed Project, 121
- adjustment disorder and, 88–89
- among asylum seekers, 311, 322*box*
- Bank of Hope strategies for minimizing, 115–116
- behavioural activation addressing, 430
- bereavement as, 87
- bodily stress disorder, 75
- burn-out and, 481
- burn-out as cause of, 481
- CBT and, 26–27
- communication of, in suicide risk assessment, 109–110
- counselling and, 427
- dementia and, 168
- depression caused by, 40
- detection of, by GPs, 447–449
- vs. disorder, 73
- eating disorders causing, 267–268*t*19.1
- employment-related, 359
- in ethnic minorities, 307
- among GPs, 480–481, 483
- GPs' evaluation of physical problems and, 44*box*4.2
- help-seeking and, 30, 31
- major depression and, 87
- management of, 447
- medication for, 32, 33
- mindfulness-based reduction of, 132–133, 180
- mindfulness-based therapy addressing, 432–433
- over sexual problems, 327
- in patients, 43, 49–50*box*
- PC vs. specialist interests in, 447
- PCMH consultations prompted by, 3
- PHQ-9 scores for, 88*box*7.1
- during pregnancy, 358
- psychological therapies for, 420, 422*box*29.1
- as psychosis precursor, 214*box*15.1
- racial minorities' experiences of, 29–30
- safety plans addressing, 113*t*, 117
- social stress, 71*t*6.1
- solution-focus therapy addressing, 117
- suicide and, 108, 112*box*8.3, 114, 116*box*8.4
- timing of depression treatment and, 89
- trigger identification, 116*box*8.4
- Sub-Saharan Africa, 54
- substance misuse/abuse anxiety disorders and, 75–76
- burdens of, 373
- coexisting with other disorders, 75–76
- depression and, 90*box*7.2
- eating disorders and, 268
- among GPs, 484
- mental illness caused by, 253
- mortality and, 279*t*20.1
- in prisoners/offenders, 343, 344
- in psychosis, 216
- SDGs for, 59
- starting ages of, 354*t*25.2
- suicide and, 108, 231–232*box*16.2
- sub-threshold disorders
- in bulimia nervosa, 268
 - characteristics of, 76
 - depression-related, 76, 88, 89, 91
 - is eating disorders, 273
 - in prisoners/offenders, 343
 - seriousness of, 76
 - transitioning to threshold disorder, 353
- Sudan, 61
- suicide (general). *See also* self-harm
- among asylum seekers/refugees, 317
 - in children and adolescents, 201
 - depression and, 104, 118
 - distress and, 104, 114
 - in ethnic minorities, 231–232*box*16.2
 - among GPs, 480, 481, 484
 - GPs addressing bereavement caused by, 118
 - hope vs., 119–120*box*
 - hopelessness and, 91, 105, 108–110, 109*box*8.2, 113, 127
 - impact of, 118
 - interventions for reduction of, 233–234
 - LTCs and, 112*box*8.3
 - mental disorders/illness and, 112*box*8.3, 115
 - morbidity and, 103, 118, 201
 - mortality from, 103, 107*box*8.1, 118, 231
 - parental issues and, 231–232*box*16.2
 - personality disorders and, 112*box*8.3
 - physical health problems and, 104
 - prevalence of, 356*t*25.5
 - in prisoners/offenders, 231–232*box*16.2, 345

- suicide (general) (cont.)
 rates of, 231
 risk factors and assessment, 107–108, 118, 231–232*box*16.2, 233, 449–450*box*30.2
 same-sex orientation and, 231–232*box*16.2
 socioeconomic status and, 231–232*box*16.2
 stress caused by, 103
 the wish to feel better vs., 116*box*8.4, 119–120*box*
 young people and, 114
 suicidal behaviour/attempts
 assessment of, 107–111, 112*box*8.3
 causes of, 104
 as a continuum, 103–104, 107, 109*box*8.2
 diagnostic criteria for, 72*t*6.2
 masculine sociological standards and, 28
 prevalence of, 356*t*25.5
 stress accompanying, 107–108
 vs. suicidal thoughts, 103–104
 as suicide precursor, 103, 107–108, 231–232*box*16.2, 231, 233
 by women, 231–232*box*16.2
 by young people, 114
 suicidal thoughts/ideation. *See also* self-harm
 assessment of, 108–112, 109*box*8.2, 111*fig*8.3, 112*box*8.3
 Bank of Hope strategies for minimizing, 116*box*8.4
 benzodiazepine use and, 244
 in case studies, 113
 in case study, 113
 causes of, 103–104, 105
 in children and adolescents, 205*t*14.1
 deaths by, in the UK, 103
 depression and, 127
 development of, 104, 105*fig*8.1
 distress and, 103–104
 leading to attempts, 110–111
 mental disorders/illness and, 104
 mental state examination and, 112*box*8.3
 patient confidentiality and, 111
 patients' disclosure of, 108–110, 111, 119–120*box*
 physical health problems and, 105
 prevalence of, 356*t*25.5
 in psychosis, 216
 rates among women, 103
 referrals to health services for, 233–234
 vs. suicidal behaviour/attempts, 103–104
 trigger events of, 112
 in young people, 114
 suicide prevention
 overview, 103–119
 Bank of Hope strategies for, 115, 116*box*8.4
 barriers to, 103
 collaborative care in, 115, 119–120*box*
 compassion in, 103, 106, 119
 cost savings for, 364
 GPs' roles in, 103, 104, 106, 115, 117–118, 119–120*box*
 high risk groups as priorities for, 232
 intervention economics of, 362*t*25.6
 interventions for, 359, 360
 key points of, 119–120*box*
 medication in, 118, 193
 patient-monitoring after hospitalization and, 233
 PCMH's roles in, 104
 physical health problems and, 119–120*box*
 QOF and, 104
 referrals to mental health services, 115
 resources for, 121
 risk assessment and mitigation in, 103, 232
 safety plans for, 103, 112, 113*t*, 115–116, 117
 solution-focused therapy for, 119
 strategies for, 103, 112, 113*t*, 115, 116*box*8.4
 suicide-means access limitations in, 233
 Triangle of Care in, 111
 Sumathipala, Athula, ix–x, 54–64
 Survivors Speak Out campaign, 39–40
 Sustainable Development Goals (SDGs), 58*box*5.2, 59, 64
 Sweden, 374, 375, 453
 Switzerland, 60*t*5.2, 375
 talking therapies. *See also* cognitive behavioural therapies
 accessed by ethnic minorities, 304
 aims of, 420
 for alcohol use problems, 257
 in case studies, 159
 for common mental health problems, 25
 consumerism and, 26–27, 31–32
 costs of, 33
 counselling in, 426–427
 for depression, 159
 patients' preferences for, 46, 49–50*box*, 403, 405
 patients' trust gained by, 115
 for prisoners/offenders, 348
 as psychological therapy basis, 420
 Tang, Eugene, ix–x, 153, 172*box*11.8
 Tanzania, 61
 teaching and learning about mental health
 overview, 439–456
 attitude problems in, 447, 456*box*
 Balint groups in, 453
 barriers against change in, 455
 Cambridge–Calgary model for, 451
 communication and interview skills requirements in, 447, 449–450*box*30.2
 in community vs. institutional settings, 439
 core GP competencies for, 439–446, 440*t*30.1–445*t*30.1
 current developmental stages for, 439
 curriculum for, 439
 depression management in, 449–450*box*30.2

- digital recordings/DVDs in, 450, 451–453
- effectiveness of, 455–456
- evaluation of, 453, 454*t*30.2
- feedback (audio-visual) in, 451*box*30.3, 452*box*30.4, 453, 456*box*
- Gotland study in, 453
- for GPs, 439
- GPs' vs. specialists' interests in, 447, 456*box*
- key points of, 456*box*
- knowledge and skills requirements in, 448*box*30.1
- knowledge gaps in, 446–447, 456*box*
- in LAMI countries, 439, 454, 455
- mental health education in PCMH, 439–446
- problem-based interviewing in, 451, 452*box*30.4
- psychosocial interventions in, 446
- QOF applied to, 6
- quality of care improved and, 453–455
- RCGP curriculum for, 439, 446
- recommendations for, 455–456
- role playing in, 450–451, 456*box*
- skill development in, 447–453
- skills modelling in, 450
- skills required for, 447, 449–450*box*30.2
- skill-teaching methods, 450–453
- SMI research in, 454–455
- specialists' vs. PCMH GPs' interests in, 447, 456*box*
- telephone-based therapy and support
- access to mental health and, 379, 387*box*27.1, 391, 394–395
- in case study, 179*box*12.2
- in collaborative care, 404, 412–413
- as developing modalities, 97
- for ethnic minorities, 314
- IAPT services using, 390–391
- in nurse-led interventions, 379
- for postnatal depression, 191
- in suicide prevention safety plans, 117
- Thomas, Laura, ix–x, 12, 21*box*1.2
- tobacco use disorders. *See* smoking
- treatment decisions
- overview, 473–478
- antidepressant medication in, 473–474, 476, 479*box*
- in case studies, 473–475, 476–477, 478
- on depression, 473–475, 476–477, 478
- guideline recommendations for, 473–474
- key points of, 479*box*
- physical health considerations in, 474–475, 479*box*
- the PICO approach in, 476*box*32.1, 476–478, 479*box*32.2
- for primary- vs. secondary-care patients, 474, 475, 479*box*
- research needed for, 478
- trial evidence application in, 475–478
- tuberculosis, 57, 58*box*5.2, 58, 278*box*20.1
- Turkey, 18*t*2.1
- Tylee, Andre, ix–x, 87–98
- United Nations Development Programme (UNDP), 56*box*5.1
- United States
- access to mental health care for ethnic minorities in, 305*box*21.2
- alcohol use problem screening in, 254
- the American bypass to psychiatric care, 14
- antidepressants prescribed for young people in, 33
- behavioural health service care in, 7
- collaborative care in, 179, 403–404
- DART programme in, 6
- diabetes in, 285
- dyslipidaemia in, 281
- early psychosis intervention in, 216–217
- health expenditure in, 60*t*5.2
- health insurance coverage in, 217–218
- HMO system in, 14
- migrants' ethnicities in, 300
- National Comorbidity Survey of, 14
- neuropsychiatric disorders and, 97
- nurse training in, 377–378
- PCMH in, 6
- psychiatric disorder prevalence in, 18*t*2.1
- search back from, 179
- self-help therapies in, 48
- stepped care formulated in, 403
- stepped care trials in, 408
- Veteran's Administration and SMI care, 406
- universal health coverage (UHC), 7, 58*box*5.2, 59, 361–364
- van Beljouw, M.J., 411
- Waheed, Waquas, ix–x, 300–307
- Wales, 7, 294, 343, 345
- Watts, C. A. H. and B., 1
- Wessex Research Network (WRn), 467, 468, 469
- WHO. *See* World Health Organization
- women. *See also* child mortality; maternal health issues; nurses; perinatal mental health problems
- alcohol intake guidelines for, 251
- alcohol use problems in, 251
- AMP psychosocial intervention for, 390
- anxiety rates among, 16, 125
- anxiety screening in, 127
- as asylum seekers/refugees, 313, 316, 317–318, 319
- depression rates among, 16, 29–30, 40–41
- eating disorders among, 268–269
- eating disorders in, 268–269, 273–274*box*xu

- women (cont.)
 family/social connections of
 as advantages to, 28
 help-seeking responses in, 73
 life expectancy reduced by
 mental disorders, 355*t*25.4
 major depression in, 89–90
 osteoporosis in, 291
 overrepresentation of, in
 PCMH, 27–28
 as prisoners/offenders,
 343–344, 349
 psychological therapies used
 by, 386
 self-harming rates among, 16
 sexual problems as defined
 by, 327
 sexual problems in, 329*t*23.1,
 329, 330, 331, 332,
 336–337, 339*box*
 Strong-Black-Woman self-
 image, 29–30
 suicide in, 103,
 231–232*box*16.2, 231, 484
 suicide-related PCMH
 sought by, 106
- weight changes in, 289
- World Bank, 16–17, 55, 56*t*5.1,
 58*box*5.2
- World Health
 Organization (WHO)
 Collaborative Study of
 Psychological Problems in
 General Healthcare, 74–75
- Commission on
 Macroeconomics and
 Health, 58*box*5.2
- Commission on Social
 Determinants of Health,
 58*box*5.2
- depression treatments
 developed by, 97
- Disability Assessment
 Schedule, 81
- on mental health, 2
- Mental Health Expert
 Committee of the World
 Health Organization, 54
- mental health training
 programmes established
 by, 61
- mhGAP of, 54, 62, 64, 79, 81
- on PCMH, 2
- Strategies for Extending
 Mental Health Care
 programme, 61
- World Mental Health
 Surveys, 14, 20, 110–111
- years lived with a disability
 (YLDs), 89–90, 353, 373,
 401. *See also* burdens of
specific mental disorders
 young people. *See also*
 child and adolescent
 mental health
 problems
 access to mental health care
 for, 390
 cannabis use in, 215, 243
 diabetes in, 286
 eating disorders among,
 268–269, 270
 eating disorders in,
 273–274*box*u
 help-seeking for sexual
 problems, 327
 mortality in, 57, 58, 278